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Chronic hepatitis B infection remained one of the most prevalent infectious diseases inflicting 
mankind. In spite of several decades of intense research, many aspects of its life cycle and 
host-viral interaction remain unclear. The virus, through mimicking the splicing signals on its 
coding sequence, was able to hijack the human splicing mechanisms to delete a large section 
of its genome at precise sites to generate the HBV splice variants. The reason for this 
apparently wasteful but conserved mechanism is still not well understood. The work in this 
thesis focused on finding the biological roles of HBV RNA splicing, and through studying of 
human samples, to determine if there is any clinical importance, either as a marker or a 
potential target for therapy. We first refined the tools to precisely quantify the HBV splice 
variants from the DNA derived from human serum. Besides confirming earlier finding that 
splice variants were common and abundant in chronic infection, the results demonstrate that 
the levels rise during the immune clearance phase and peaked just before HBeAg 
seroconversion. Further test of hypothesis showed that this can be linked to the inhibition of 
the HBV polymerase function, possibly through a direct or indirect effects of the interferons. 
The co-transfection experiments showed that the most common single-spliced defective HBV 
genome (SP1) enhanced replication of wild-type HBV DNA.  The expression plasmid 
transfection experiments provided evidence to support the hypothesis that core protein is the 
rate-limiting factor of the viral replication, and that HBV RNA splicing, producing dedicated 
“core mRNA” to support viral replication. This could be the reason why the splicing 
mechanism remains conserved across all HBV genotypes. Small interfering RNA targeting 
the splice donor and acceptor sites, and the PRE region were tested and were found to be 
effective in suppressing the viral expression and replication. Future plan to study the splice-
generated protein and viral protein presentation to the immune system, as well as validating 
its use as a clinical prognostic marker is discussed.            (327 words) 
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Chapter 1: Introduction 
 
1.1   Hepatitis B Virus Biology 
 
Chronic hepatitis B, a highly prevalent infection in Asia, afflicts 350 million persons 
worldwide. It causes severe complications, which include liver cirrhosis, liver failure and 
liver cancer (Beasley 1988). Deaths from liver cancer caused by hepatitis B alone probably 
exceeds one million a year worldwide (Evans 1998, Parkin 1999). Despite an effective 
vaccine which has been available for over 30 years, attempts at treatment of chronic 
infections have had only limited success so far. 
 
 
1.1.1 Landmarks in the discovery of HBV biology 
 
Despite very early recognition of an epidemic disease that caused jaundice in the affected 
patients (fifth century B.C.), "hepatitis B" as a distinct disease entity was only recognized in 
the 1940s, after a series of studies which eventually defined two infectious diseases 
characterized by different incubation periods and modes of transmission (MacCallum 1944, 
Paul 1945, Neefe 1946). In 1947, MacCallum proposed the name hepatitis A for the 
enterically-transmitted form with shorter incubation, and hepatitis B for the form transmitted 
through blood products, and a longer incubation period (MacCallum 1947). 
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The next breakthrough came in 1965 when Blumberg and colleagues described the Australian 
Antigen in leukaemia sera (now known as hepatitis B surface antigen (HBsAg)) (Blumberg, 
Alter et al. 1965), for which he was awarded a Nobel Prize in 1976. Subsequent studies 
revealed that this ‘Australian Antigen’ was specific to the sera of acute and chronic hepatitis 
B patients (Blumberg, Sutnick et al. 1969). Dane and colleagues discovered virus-like 
particles that carried this antigen on their surface in hepatitis B patients using immune 
electron microscopy in 1970 (Dane, Cameron et al. 1970) (Figure 1.1). These "Dane 
particles" were consequently identified to be the hepatitis B virus. In 1971, Krugman et al. 
found that a specific hepatitis B immune serum globulin preparation could prevent hepatitis B 
among children (Krugman, Giles et al. 1971). In the same year, Krugman et al. accomplished 
the active vaccination for hepatitis B with a crude vaccine, a heat-inactivated infectious 
serum (Krugman, Giles et al. 1971). In 1973, hepatitis B viral DNA polymerase activity was 
identified in human sera rich in Dane particles (Kaplan, Greenman et al. 1973). As techniques 
for cloning and amplification of DNA became available by the end of the seventies and the 
early eighties, the virus genome was cloned and sequenced. It was proven that the hepatitis B 
viral DNA encoded the surface protein, core protein of the Dane particle, a putative DNA 
polymerase and a protein of unknown function, designated the X protein. In 1982, Summers 
and Mason opened up a new phase in HBV research by characterizing the mechanism of 
HBV replication (Summers and Mason 1982). In 1994, Bock and colleagues revealed the 
nucleosomal organisation of the hepatitis B virus genome in the nucleus of the infected 




Figure 1.1. Schematic model of the Dane particle and incomplete particles that are 















1.1.2  The HBV genome 
HBV is a non-cytopathic, hepatotropic virus with a 3.2 kb circular partial-double stranded 
DNA genome (Figure 1.2). This is converted into cccDNA in the nucleus of the infected 
hepatocyte and serves as template for transcription of the pregenomic/precore mRNA and 
subgenomic RNAs. Although there are several promoters, all viral RNAs terminate at a 
common polyadenylation signal. HBV is distantly related to retroviruses and contains four 
ORFs—core (C), reverse transcriptase-polymerase (P), surface (S) and X—which are all 
encoded on the positive strand. Subgenomic pre-S and S RNAs encode three viral surface 
proteins, all expressed from a single ORF, whereas the small 0.7 kb RNA encodes the X-
protein (Ganem and Varmus 1987). In addition to its function as a template for reverse 
transcription into genomic minus strand DNA, the bicistronic pregenomic RNA (pgRNA) 
serves as mRNA for translation of the core and P-proteins. The precore mRNA initiates 
upstream of the pgRNA and the precore region serves as the translation template for synthesis 











Figure 1.2  HBV genome map and location of post-transcriptional regulatory element 









1.1.3   The Life Cycle of HBV 
 
1.1.3.1   Binding and Entry 
 
The initial phase of HBV infection involves the attachment of mature virions on to the host 
cell membrane. Viral attachment often determines host and tissue specificity of a virus. 
However, for HBV, there are no cell-lines available that are able to support viral replication 
until the establishment of a polarizable HBV-susceptible human hepatoma cell line 
(HepaRG) (Gripon, Rumin et al. 2002). Since then, important insight into viral and cellular 
determinants participating in HBV binding and infection have been achieved. Although the 
precise HBV receptor is still not established, the current understanding is that the large viral 
surface protein (L) (of the HBV envelope) plays a pivotal role in HBV entry (Schulze, Gripon 
et al. 2007). It mediates diverse functions, commencing binding of virions to heparin sulfate 
proteoglycans at the hepatocytes surface as a prerequisite for entry. This is followed by a 
highly specific process involving the myristoylated N-terminal pre-S1 subdomain of L 
(Gripon, Le Seyec et al. 1995, Bruss, Hagelstein et al. 1996), as well as the cytosolic and 
antigenic loops of the S-domain, which initiates a series of less well understood steps, 
resulting in a pH independent, reduction-sensitive fusion of the viral membrane with a 
cellular membrane. One of these steps is highly sensitive to synthetic N-acetylated pre-S1 
lipopeptides and can be blocked in vitro and in vivo at picomolar concentrations (Gripon, 
Cannie et al. 2005).  
 
Many proteins have been found associated with the various hepatitis B surface proteins, 
including apolipoprotein H (apo-H) (Mehdi, Kaplan et al. 1994), an altered form of 
apolipoprotein H (alt. apo-H) (Mehdi, Yang et al. 1996), poly-human serum albumin (pHSA) 
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(Pontisso, Ruvoletto et al. 1989), fibronectin (Budkowska, Bedossa et al. 1995), interleukin-6 
(IL-6) (Neurath, Strick et al. 1992) and  more recently, a protein (gp180) has been identified 
to interact with the preS1 domain in Duck HBV (Breiner, Urban et al. 1998). Some studies 
suggest that the pre-S1 domain, involved in binding to cells and S protein, may also be 
important in interacting with cells by binding the human liver protein - Annexin V (De 
Meyer, Gong et al. 1997).  
 
Despite these findings, the precise proteins and mechanism involved in HBV entry into cells 
is still not conclusive until recently. By using primary Tupaia hepatocytes (PTH) and cultures 
of differentiated HepaRG cell models, the specific receptor binding site of HBV has been 
narrowed down to a critical region of the pre-S1 protein spanning amino acid (aa) residues 9- 
18, with aa residues 29-48 enhancing infection inhibition, whilst aa residues 19-28 and 1-8 
were dispensable (Meier et al. 2013). At around the same time, scientists led by Professor 
Wenhui Li and colleagues, identified the sodium taurocholate co-transporting polypeptide 
(NTCP) as a functional receptor for HBV and HDV. By using zero distance photo-affinity 
cross-linking and mass spectrometry, these investigators identified NTCP as a receptor for 
the HBV pre-S1 peptide. The NTCP is an integral membrane protein, localized to the 
basolateral plasma membrane of hepatocytes, and normally involved in bile acid transport in 
the liver. The investigators used a number of different experimental approaches to confirm 
the role of NTCP as a receptor, including knockdown of NTCP mRNA by siRNA, which 
rendered primary human hepatocytes and PTH resistant to HBV infection. The authors 
further produced HCC cell lines stably expressing NTCP and subsequently infected them 
with HBV or HDV. Immunofluorescence staining clearly demonstrated the expression of 
HBV and HDV proteins in these cell lines, plus a 2-4-fold increase of viral RNA and DNA 
after infection in the cell line by real-time PCR. Southern blotting also showed the presence 
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of HBV covalently closed circular DNA in the infected cell. Furthermore, sequence swapping 
of nine amino acids in the NTCP taken from non-susceptible monkeys with the 
corresponding sequence from the human form of this protein converted the monkey NTCP 
into a functional receptor for both viruses (Yan et al. 2012). The discovery of NTCP as a 




1.1.3.2   Uncoating and Nuclear Transport 
The HBV penetrates the cell membrane through virus-cell fusion and then the viral envelope 
is removed. The subsequent steps before nuclear transport is less clear. Some studies suggest 
that a proteolytic event must occur on the large surface protein to expose a membrane fusion 
domain (Lu, Block et al. 1996). However, it is believed that this occurs at the plasma 
membrane and not within an acidic vesicle (Kock, Borst et al. 1996). After uncoating, the 
nucleocapsid is believed to be transported to the nuclear membrane. The DHBV system has 
suggested that HBV genome uncoating occurs at the nuclear membrane (Qiao, Scougall et al. 
1999). 
 
1.1.3.3   HBV Genome Repair and Transcription 
The HBV DNA entered the nucleus where it is repaired to the covalently closed-circular form 
(cccDNA). The repair involves the completion of the dsDNA form, removal of the 5' terminal 
structures (an RNA primer and the polymerase protein), as well as covalent ligation of the 
strands. The hepatitis B polymerase protein is not required at this stage (Kock and Schlicht 
1993). Once recircularized to form the cccDNA, enhancer and promoter activities start 
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producing the various HBV transcripts required for HBV protein synthesis and pregenomic 
RNA (pgRNA) generation.  
 
The HBV cccDNA is the template for subgenomic and genomic mRNA that are 3.5, 2.4, 2.1, 
and 0.7 kb long respectively (Chisari 1997). The smaller, subgenomic transcripts include the 
mRNA for the expression of the transcriptional transactivating protein (X), and the large, 
medium and small surface (S) proteins. The larger genomic transcripts are longer than one 
genome in length and serve to produce e, core (C) and polymerase (P) proteins (Figure 1.3). 
One genomic transcript, lacking the ATG start codon for the e protein, is designated the 
pgRNA since it is chosen specifically by the HBV polymerase protein for packaging (Enders, 




Figure 1.3   Transcripts and promoters. The numerical designations on the HBV genome 
[0-3221 base pairs (bp)] are based on the HBV subtype adw2. S, C, X and P represent the 
genes encoding hepatitis B surface antigen, core/e antigen, x protein and polymerase. Pre-S1, 
pre-S2, Xp and Cp represent the promoter elements for the corresponding genes. The 
enhancer elements are designated as Enhancer (Enh) I and II. An, the single polyadenylation 
site, is utilized by all the HBV RNAs. The HBV transcripts are shown outside of the genome. 
Each viral transcript is labelled with its respective length in kilobases and a poly A tail at the 




1.1.3.4   Nucleocapsid Assembly 
Once sufficient quantities of HBc protein are synthesized and at least one polymerase protein 
has been translated, these proteins assemble to form nucleocapsid, which contain the 
pregenomic RNA, hsp90 and protein kinase C. The encapsidation is believed to start only 
when the viral polymerase bound to the stem-loop sequence (ε) at the 5’ end of pgRNA and 
the C-terminus of the polymerase interacts with the hepatitis B core protein (Nassal and 
Schaller 1996). The arginine-rich region of core protein and, consequently, the RNA binding 
ability is essential for pregenomic RNA encapsidation (Nassal 1992). Expression of core and 
polymerase proteins alone does not result in the encapsidation of polymerase proteins 
(Bartenschlager and Schaller 1992). 
 
1.1.3.5   HBV Viral DNA Synthesis 
Reverse transcription/DNA replication is believed to be initiated upon commencement of 
encapsidation. The complex mechanism employed by HBV to convert its pgRNA into 
dsDNA is now well characterized (Figure 1.4). The transcription of the 3.5 kb pgRNA results 
in the generation of a terminally redundant RNA strand. A sequence, comprised of about 200 
nucleotides, including direct repeat 1 (DR1) as well as the -stem-loop, is included. Another 
copy of DR1 is located near the 3' end of the RNA and denoted as DR2. Upon binding of the 
polymerase to the -stem-loop, the polymerase begins to reverse transcribe the pgRNA 
template for three to four bases. The polymerase protein is covalently attached onto the 
growing (-) DNA strand and serves as a primer when initiating reverse transcription. Reverse 
transcription of the pgRNA generates the (-) DNA strand, which becomes terminally 
redundant due to the nature of its terminally redundant template (Summers and Mason 1982, 
Miller, Marion et al. 1984, Wang and Seeger 1992). 
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As (-) DNA occurs, the newly copied pgRNA template is degraded by RNase H activity of 
the polymerase protein (Miller, Marion et al. 1984). However, the 15 to 18 capped oligo-
ribonucleotides at the 5' end of the pgRNA remain undegraded once the (-) DNA strand is 
completed, which serves as the primer for (+) DNA strand synthesis. The newly generated 
RNA primer is moved and base-paired to the 5' DR2 region on the (-) DNA strand (Loeb, 
Hirsch et al. 1991).  
 
Once translocated, (+) DNA strand synthesis begins and continues to the end of the 5' end of 
the (-)DNA strand. To complete (+) DNA strand synthesis, an intramolecular transfer is 
required to give the (+) DNA strand access to the uncopied portion of the (-) DNA strand. 
Typically, the (+) DNA strand is not completed until re-entry of the virion into a host cell. 
This yields the characteristic single-stranded gap seen in packaged incomplete dsDNA 






Figure 1.4   Replication of the HBV genome. The virion DNA is brought to the cell nucleus 
and converted to cccDNA which is then transcribed to various RNAs, one of which servers as 
template for the polymerase and core protein. These two proteins assemble together with 
pgRNA to the replication complex. The reverse transcription starts at the primase (♦). During 
elongation of the minus strand, the reverse transcriptase (●) probably remains linked to the 
primase. The RNase H cleaves the RNA of DNA/RNA hybrids, leaving a complete, single-
stranded DNA minus strand. The remaining 18 bases from the 5’ terminal part of the pgRNA 
are able to shift from DR1 to DR2, where they serve as primer for the DNA plus strand after 
a template switch of the reverse transcriptase. Multiplication of the HBV genome occurs via 






1.1.3.6  Budding and Secretion of Mature Virions and Non-Infectious 
Particles 
 
The S (Surface) ORF contains three in-phase start sites and codes for a family of hepatitis B 
surface antigen proteins, namely the small hepatitis B surface proteins (SHBs), the middle 
hepatitis B surface proteins (MHBs) and the large hepatitis B surface proteins (LHBs), that 
make up the viral envelope. Due to the varying amounts of the different surface protein 
transcripts, much more SHBs and MHBs are produced compared to the LHBs. These proteins 
are co-translated in the endoplasmic reticulum (ER) due to a shared S-domain, which 
contains several transmembrane spanning sequences. The hepatitis B surface proteins 
aggregate in regions of the Golgi complex in a process which excludes host proteins from the 
complex. Regions high in SHBs protein with minimal MHBs are able to bud into the lumen 
of the ER to produce the secreted 22nm particles (Figure 1.1) (Cheng, Smith et al. 1986, 
Standring, Ou et al. 1986).  
 
The completed nucleocapsid is thought to associate with areas of the Golgi high in HBV 
surface protein content. LHBs is believed to interact with the HBc protein at the cytoplasmic 
face of the Golgi, pulling the nucleocapsid into the forming vesicle, resulting in the 42 nm 




Figure 1.5   Life cycle of HBV. The virus, shown above, with its typical relaxed circular 
DNA genome, enters the hepatocyte and the DNA is transported to the nucleus and processed 
to covalently closed circular DNA (cccDNA) that is the template for transcription of viral 
RNA. As viral RNA enters the cytoplasm, one of the largest, pregenome RNA, serves as 
mRNA for the viral reverse transcriptase (RT) and core protein synthesis. RT binds in cis to 
its own mRNA and this complex is packaged into immature viral nucleocapsids. Following 
completion of minus strand DNA synthesis, and at least partial completion of plus strand 
DNA synthesis, the nucleocapsids bind to viral envelope proteins, bud into the endoplasmic 
reticulum (ER) and, ultimately, exit the cell. At low concentrations of viral envelope proteins, 
nucleocapsids are transported to the nucleus to amplify cccDNA copy number (Rajen Koshy 
1998). 
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1.2 Hepatitis B infection 
 
1.2.1 HBV: the disease 
 
HBV causes acute and chronic infections of the liver. Acute hepatitis B may produce serious 
illness, and approximately 0.5% terminates with fatal, fulminant hepatitis. Chronic HBV 
infection induces a spectrum of clinical manifestations, ranging from mild, unapparent 
disease to fulminant hepatitis, severe chronic liver disease and cirrhosis. The virus also has 
been clearly implicated in the development of primary hepatocellular carcinoma (HCC), one 





Hepatitis B infection is a global public health problem and it is estimated that there are more 
than 350 million chronic HBV carriers worldwide. The prevalence of HBV infection varies in 
different geographical areas, ranging from <1% of the population in US and Europe, to as 
high as 10-20% in China and sub-Saharan Africa. In Singapore, the overall HBsAg carrier 
rate in the generally population is estimated to be approximately 4.1% and the incidence rate 
of primary liver cancer ranks as the fourth most common cancer for male in 1999 (James, 
Fong et al. 2001). 
 
In adults, 90-95% of cases resolve spontaneously with varying degrees of severity of acute 
hepatitis B. The remaining 5-10% of adults develops chronic hepatitis B. However, in 
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children infected between the ages of 1 and 5 years, 29-40% of them have chronic hepatitis. 
In contrast, the chronicity can be as high as 90% in infants born to HBeAg positive mothers. 
This mother-to-infant vertical transmission perpetuates the chronic infection from generation 
to generation (Stevens, Beasley et al. 1975). The ratio of males to females with hepatitis B 





Transmission of HBV is largely through the parenteral route, from the exposure to blood 
from HBV-infected individuals. Currently, the risk of HBV transmission by transfusion of 
screened blood is very small since all blood donors are screened for the presence of HBsAg 
from the 1980s (Schreiber, Busch et al. 1996). Percutaneous inoculation of blood or body 
fluid still plays a major role in the transmission of hepatitis B infection. Needle sharing by 
intravenous drug users, reusing of contaminated needles for tattoos, acupuncture and ear 
piercing all facilitate transmission of hepatitis B. Sexual spread of hepatitis B among 
homosexuals as well as heterosexuals also appears to occur. The presence of large amounts of 
virus in the blood and secretions of infected persons, which persists over a long time, means 
that even an isolated, single and minute exposure can transmit this infection. The spread is 
facilitated by the fact that many chronic HBsAg carriers are asymptomatic and unaware of 
their infection and potential infectivity. 
 
The most important mode of transmission of hepatitis B is perinatal spread from HBV-
infected mothers (mother to child). In high prevalence areas, such as Hong Kong and China, 
perinatal transmission accounts for 40 to 50% of chronic HBV infection (Stevens, Beasley et 
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al. 1975, Lok, Lai et al. 1987). In areas of low endemicity, mother-child or child-child 
transmission is rare. 
 
 
1.2.4   Clinical manifestation and diagnosis 
 
The clinical presentation of HBV can range from inactive carriers with no clinical symptom, 
to severely ill patients with jaundice, oedema, ascites, upper gastrointestinal bleeding and 
rapid death from liver failure. 
 
 
1.2.4.1   Acute Hepatitis B 
 
The acute form of the disease often resolves spontaneously after a 4-8 week illness. Most 
patients recover without significant consequences and without recurrence. However, a 
favourable prognosis is not certain, especially in the elderly who can develop fulminating, 
fatal cases of acute hepatic necrosis. Young children rarely develop acute clinical disease, but 
many of those infected before the age of seven will become chronic carriers (Previsani 2002). 
 
The incubation period of acute HBV infection is from 1 to 4 months. In patients with clinical 
illness, the onset is usually insidious with tiredness, anorexia, vague abdominal discomfort, 
nausea and vomiting, sometimes arthralgia and rash, often progressing to jaundice. Fever 
may be absent or mild (Hollinger 2001). The icteric phase of acute viral hepatitis begins 
usually within 10 days of the initial symptoms with the appearance of dark urine followed by 
pale stools and yellowish discoloration of the mucous membranes, conjunctiva, sclera, and 
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skin. Jaundice becomes apparent clinically when the total bilirubin level exceeds 20 to 40 
mg/l. It is accompanied by hepatomegaly and splenomegaly. About 4-12 weeks thereafter, 
the jaundice disappears and the illness resolves with the development of natural, protective 
antibodies (anti-HBs), in about 95% of adults. 
 
Diagnosis. Acute hepatitis B is characterized by the presence of anti-HBc IgM serum 
antibodies converting to IgG with convalescence and recovery, and the transient (<6 months) 
presence of HBsAg, HBeAg, and viral DNA, with clearance of these markers followed by 
seroconversion to anti-HBsAg and anti-HBeAg. More than 90% of adult-onset infection 
cases fall into this category. The remaining 5 to 10% of adult-onset infection and over 90% of 




1.2.4.2   Chronic Hepatitis B 
 
Chronic hepatitis B is defined as a chronic necroinflammatory disease of the liver caused by 
persistent infection with hepatitis B virus. The diagnosis of chronic HBV is based on the 
detection of HBsAg in the serum for 6 months or more. It is characterized by persistent HBV 
infection associated with inflammation and hepatocellular necrosis, or without any evidence 
of liver disease (Guidotti, Dong et al. 2001). Many patients with chronic HBV infection are 
asymptomatic, whereas others have nonspecific symptoms such as fatigue. Patients with 
chronic HBV infection may experience exacerbations that may be asymptomatic or mimic 
acute hepatitis with fatigue, anorexia, nausea, and jaundice, and in rare instances, progress to 
hepatic decompensation. A few chronic patients eventually show normalization of liver 
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enzymes and clear the infection with the development of anti-HBs (0.5% per year) (Guidotti, 
Dong et al. 2001), while others do not resolve the infection and may develop cirrhosis, liver 
failure and HCC (Figure 1.6). 
 
 










Chronic hepatitis B infection is a dynamic process with replicative and non-replicative (or 
low replicative) phases based on virus-host interaction. Figure 1.7 described one of the most 
widely accepted models of the natural history of progression of chronic HBV infection. In 
this model, the presence of circulating HBsAg, HBeAg and high level of serum HBV DNA 
characterizes the immunotolerant phase, which is seen in patients with perinatal infection and 
often lasts for decades. During this phase, patients have no symptoms, normal or slightly 
increased serum alanine aminotransferase (ALT) levels, and minimal histological activities. 
Once the tolerant effect is lost during the course of chronic HBV infection, patients may enter 
the second phase - the immune clearance phase, which is associated with a decrease in HBV 
DNA concentration and increased ALT levels and histological activity, reflecting immune-
mediated lysis of infected hepatocytes. The second phase lasts from months to years. The 
third immune-controlled phase, which is also referred to as the inactive carrier state occurs 
after HBe-seroconversion with loss HBeAg and development of anti-HBe antibody. This 
phase is usually preceded by a marked reduction of serum HBV DNA, followed by 
normalization of ALT levels and resolution of liver necroinflammation. This inactive carrier 
phase may last for the patients’ remaining lifetime, but a proportion of patients may undergo 
subsequent spontaneous or immunosuppression-induced reactivation of HBV replication with 
reappearance of high levels of HBV DNA, with or without HBeAg SC and a rise in ALT 
levels (immune-escape). Patients who have loss of HBsAg and seroconversion (anti-HBs 
antibody positive) are diagnosed as having resolved hepatitis B (Guidotti, Mallet et al. 2001). 
 
There are however new lines of evidence that emerge in the last few years that this model 
may be overly simplistic. For example, Kennedy et al. (Kennedy, Sandalova et al. 2012) 
demonstrated that young patients (under 30 years of age) with chronic hepatitis B (CHB) had 
more HBV-specific T cells with the ability to proliferate and produce cytokines than adult 
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patients with CHB, implying that they were not associated with an immune profile of T-cell 
tolerance. On the contrary, children and young adults with chronic HBV infection have an 
HBV-specific immune profile that is less compromised than that observed in older patients. 
To make issues more complex, patients with low ALT often have better HBV-specific T cell 
immunity that those with high ALT, underlying the complex interaction between the virus 
























Chronic HBV infection is found to be an important cause of morbidity and mortality in 
follow-up studies of chronic hepatitis B patients in HBV endemic areas. Progression from 
chronic hepatitis to cirrhosis and from compensated cirrhosis to hepatic decompensation and 
HCC has been estimated to be 12 to 20%, 20 to 23% and 6 to 15% at 5 years, respectively 
(Liaw, Lin et al. 1989, Demeter, Cordasco et al. 2001, Rischitelli, Harris et al. 2001). The 
lifetime risk of a liver-related death is estimated to be 40 to 50% for men and 15% for women 
among Chinese patients with chronic HBV infection. Approximately one million people die 
each year from complications of the disease that include cirrhosis, liver failure and HCC, 
making chronic hepatitis B one of the most common causes of death worldwide (Liu, Pesold 
et al. 2001). 
 
 
1.2.5    Therapeutic treatment of hepatitis B 
 
The primary objective of therapy for chronic HBV is to achieve control of viral replication 
and halt disease progression/improve liver histology. This will decrease pathogenicity and 
infectivity and thereby stop or reduce hepatic necroinflammation.  The treatment goals 
depend on the type of therapy selected: 
1. Maintaining viral suppression – achieved during antiviral treatment (i.e. nucleoside/tide 
analogue therapy or NA), that leads to viral suppression with HBV DNA reduction and 
ALT normalization.  
2. Sustained immunological control – achieved with a course of treatment of finite duration 
(i.e. Interferon α-based therapy), with the following possible outcomes: 
o In HBeAg-positive CHB: HBeAg seroconversion (lasting remission) and HBsAg 
seroconversion 
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o In HBeAg-negative CHB: HBV DNA reduction, ALT normalization (lasting 
remission) and HBsAg seroconversion 
 
The long-term goals of therapy are prevention of hepatic decompensation, progression to 
cirrhosis or HCC and, ultimately, prolonged survival (Guidotti and Chisari 2001). 
 
 
1.2.5.1  Nucleoside/tide analogues (NAs) 
 
The nucleoside/tide analogues are antiviral agent directed against the HBV polymerase that 
are able to rapidly suppress serum hepatitis B viral (HBV) DNA levels, normalize ALT, 
improve liver histology, and are generally very well-tolerated with an excellent safety profile, 
even for patients with decompensated disease. However high rates of rebound can occur both 
once the treatment is stopped, and long-term use increases the risk of the development of 
resistance to these drugs (Guidotti, Dong et al. 2001). Current treatment guidelines 
recommend initiation of therapy in HBeAg-positive patients with HBV DNA >20 000 IU/mL, 
ALT levels  2 X the upper limit of normal and evidence of necroinflammation upon liver 
biopsy. Before initiating therapy, it is recommended to monitor patients’ condition for three 
to six months to confirm the persistence of HBV DNA and ALT elevations. In patients with 
HBeAg-negative infection and elevated ALT, guidelines recommend therapy based on lower 
levels of HBV DNA (>2000 IU/mL) (Lok and McMahon 2009). 
 
Lamivudine was the first small molecule antiviral approved for the treatment of HBV. It is 
the (-) enantiomer of 2`-3` dideoxy-3`-thiacytidine. Incorporation of the active triphosphate 
(3TC-TP) into growing DNA chains results in premature chain termination thereby inhibiting 
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HBV DNA synthesis. It is moderately potent, well tolerated and affordable, but results in a 
high rate of viral resistance mutations, which increases with treatment duration, to higher 
than 60% within 5 years (Dong, Matsumoto et al. 2001, Raney, Eggers et al. 2001). In recent 
studies where LAM was used as a control arm, 36–40% of HBeAg-positive patients and 71–
72 % of HBeAg-negative patients achieved undetectable HBV DNA (as measured by 
polymerase chain reaction [PCR] assay) after one year of therapy. 
 
Other approved direct HBV polymerase inhibitors (all are nucleoside and nucleotide 
analogues) include adefovir, entecavir, telbivudine, and tenofovir. The newer, highly potent 
antiviral agents, i.e. entecavir and tenofovir, produce more effective and durable viral 
suppression, with almost no virologic resistance in previous treatment-naïve patients after 
more than 5 years of treatment (Lim, Lee et al. 2013). 
 
1.2.5.2   Interferon-based therapies 
 
Interferon alfa (IFNα) has a dual immunomodulatory and antiviral mode of action. The broad 
immunomodulatory properties include the activation of macrophages, natural killer (NK) 
cells and cytotoxic T lymphocytes, and modulation of antibody production, which results in 
enhancement of the host’s immune response to the virus. Antiviral activity is mediated by 
direct inhibition of viral replication through the activation of endoribonuclease, elevation of 
protein kinase and induction of 2’, 5’-oligodenylate synthetase. Interferon alfa was the first 
approved treatment for CHB and has been shown to favourably affect the natural history of 
the disease, largely by preventing progression to end-stage liver disease (Guidotti, Mallet et 
al. 2001). The aims of IFNα therapy are to directly inhibit viral replication on treatment as 
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well as to stimulate the host immune system to attack and eliminate HBV-infected 
hepatocytes in order to achieve a sustained response. 
 
In a meta-analysis of patients with HBeAg-positive CHB, HBeAg seroconversion rates of 18% 
higher than untreated controls have been reported following IFNα treatment (Fraioli, 
Calabrese et al. 2006). Moreover, patients achieving HBeAg seroconversion with IFNα 
treatment have higher rates of complication-free and overall survival than non-responders 
(Kennedy, Urbani et al. 2006). In HBeAg-negative CHB, rates of sustained response to 
treatment with IFNα (normalization of ALT and loss of HBV DNA, 12 months post-therapy) 
range from 16–24%, and higher rates may be achievable following extended (24 months) 
therapy (Rosmorduc, Petit et al. 1995, Liaw 2002). Sustained HBsAg seroconversion has 
been shown to occur more frequently (on prolonged follow-up) in patients treated with IFNα 
than in untreated patients (7.8% vs. 1.8%, respectively) (Fraioli, Calabrese et al. 
2006). Successful interferon therapy is more likely in patients with low level HBV DNA and 
substantial elevation of aminotransferase activity. However, those with underlying disease or 
immunosuppression are unlikely to respond to interferon therapy. There is no known 
development of IFNα-resistant viral strains. 
 
Interferon treatment may be dangerous inpatients with decompensated liver function. In 
patients with cirrhosis, interferon may lead to decompensation. IFN treatment is usually 
associated with side effects, especially flu-like symptoms, depression, neutropenia, and 
thrombocytopenia. These are normally tolerable but sometimes require dose modification 




1.4 The HBV spliced variants 
 
1.3.1  What is the HBV splice variants? 
 
A spliced hepatitis B virus transcript of about 2.2 kb was first identified in transfected human 
hepatoma cells in 1989 (Su, Lai et al. 1989). It contained a deletion of 1223 bases 
corresponding to the last codon of the core antigen gene to the middle of the surface antigen 
gene. The junction region of the deleted sequences showed the conserved splice donor and 
acceptor sequences. It was further demonstrated that this transcript could be eliminated when 
the splice acceptor site was mutated and that, although the transcript could potentially encode 
a new protein, it was not essential for viral replication. 
 
Another 2.1-kb single-spliced and a double-spliced RNA transcript were discovered in 
hepatoma cells and adjacent liver tissue in HBV infected individuals (Chen, Chen et al. 1989, 
Suzuki, Masui et al. 1989) soon after. All these transcripts had identical 5’ and 3’ ends to the 
full length pregenomic RNA, suggesting that expression of the 3.3-kb pregenomic RNA is 
regulated, at least in part, by splicing. A 2.6 kb-RNA with a splice donor site 538 nucleotides 
downstream from the donor site of the 2.1-kb spliced transcript was reported later (Suzuki, 
Kajino et al. 1990), further adding to the number of known splice sites within the HBV 
genome. 
 
From DNA purified from infected livers and the HepG2 cell line, a subgenomic HBV DNA 
complementary to the spliced viral RNA was demonstrated. The HBV RNA was packaged 
and reverse transcribed in vivo, with the cDNA being incorporated into circulating viral 
particles. This finding established the synthesis of spliced HBV RNA in vivo and indicated 
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that its reverse transcription could give rise to defective viruses (also called splice variant by 
some authors) (Terre, Petit et al. 1991) (Figure 1.8). 
 
 
Figure 1.8   Production of defective HBV and HBSP from pgRNA splicing. cccDNA: 

























1.3.2    Insights from experimental studies 
 
1.3.2.1    How is the splice variant produced? 
 
The eukaryote genome is characterised by the presence of non-coding region (introns) in-
between the coding exons (Lewin 1999). By examining the boundaries of introns and exons 
from a large number of genes in a variety of eukaryotic cells, splicing signals have been 
identified (Figure 1.8).  
5' - AG|GUAAGU – intron – YNCURA*C – YnNAG|G - 3' 
Figure 1.8   The splicing signal identified for higher eukaryotes. The vertical line (|) 
denotes the boundary between the exon and the intron, Y indicates a pyrimidine, R a purine 
and N means any base. Yn depicts a region of about nine pyrimidines. The A* is the branch 
point A that is involved in the splicing reaction. 
 
Figure 1.9 is a simplified version of how this splicing process takes place. The actual process 
involves multiple small nuclear ribonucleoproteins (snRNPs), which bind to the pre-mRNA 





Figure 1.9   RNA splicing mechanism. 
 
The HBV genome possesses the same signals at fairly specific positions, which allows it to 
utilize the human splicing mechanism to produce spliced RNA transcripts from its 
pregenomic RNA. To date, 5’ splice donor and 5’ splice acceptor sites have been identified 
(Gunther, Sommer et al. 1997, Sommer, van Bommel et al. 2000) (Figure 1.10). As single-, 
double- or even triple-spliced products have been described, the number of possible 
combinations can be very high, though predictable from the position of splice donor and 
acceptor sites within particular viral genotypes. So far, the most frequently detected splice 
variant (spliced variant 1 (SP1)) has deletions from position 2447 to 489, and has been 





















Figure 1.10   Known 5’- and 3’- splice signals in HBV genome (Gunther, 1997; Sommer, 
2000). 
3’ splice acceptor sites, putative branch sites and 
pyrimidine stretch




Figure 1.11   Types of defective HBV genomes classified according to the splice pattern. 
(Gunther et al. 1997)  
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1.3.2.2    How is the splicing process regulated? 
 
In most eukaryote cells, almost all transcribed pre-mRNAs undergo splicing to remove 
introns before being transported out of the nucleus to be translated into polypeptides. This 
splicing mechanism is linked to mRNA export, involving the splicing-dependent recruitment 
of the mRNA export factor Aly via its direct interaction with the spliceosomal protein UAP56 
(Reed 2003). Unspliced pre-mRNA will generally not be expressed and will be hydrolyzed in 
the nucleus. 
 
This contrasts with the general observation for the HBV (a DNA virus utilizing pgRNA as 
template), and RNA viruses including HIV, where the unspliced, fully functional viral RNA 
(wild-type) is the predominant form, which is exported, and packaged into new viral 
particles. Thus there must be mechanisms that suppress viral RNA splicing and facilitate the 
export of unspliced viral RNA transcripts. 
 
By constructing a series of plasmids containing HBV fragments of varying lengths, which all 
contained the major hepatitis B surface antigen (HBsAg) ORF, and observing the expression 
of HBsAg after transfection into human hepatoma Huh-7 cell line, Huang and Liang et al. 
(Huang 1993) demonstrated the existence of a genetic element within the HBV genome that 
was essential for high-level expression of viral gene products. This element was located 3' to 
the envelope coding region and was cis-acting at the RNA level. This was later named the 
post-transcriptional regulatory element (PRE) and was localized to nt 1217-1582, in the 
untranslated region of pre-S/S subgenomic RNA, and simultaneously is part of the 
polymerase and X-protein ORF of the pgRNA, and X mRNA respectively (Figure 1).  
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The PRE was evaluated in a series of studies (Huang and Yen 1994, Huang and Yen 1995, 
Donello, Beeche et al. 1996) and was found to have attributes of an RNA export element. It 
could restore export to an unspliced, HIV-derived transcript in the absence of Rev and RRE, 
and increase the export of RNA transcribed from an intronless version of the β-globin gene. 
This function was carried out in the absence of any viral protein and was presumed to be 
related to the PRE binding cellular export factors, which utilized an export pathway different 
from that of Rev and TAP proteins. Two cellular proteins, the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and polypyrimidine tract binding protein (PTB), bound to 
functionally important regions of the PRE. The significance of the former is still unclear. 
PTB was shown to shuttles rapidly between the nucleus and the cytoplasm, and increased 
PRE-dependent gene expression. (chloramphenicol acetyltransferase (CAT) expression 
plasmid) (Zang and Yen 1999, Zang, Li et al. 2001). However the introduction of consensus 
PTB sites into the same plasmid did not increase the CAT activity, implying that other 
undiscovered cellular factors may be involved. 
 
The PRE appears to harbour both splicing stimulating and inhibiting regulatory elements that 
control the processing of the viral pregenome. Heise et al. (Heise, Sommer et al. 2006) 
demonstrated a positively cis-acting splicing regulatory element (SRE-1) located at the 5’end 
of the PRE sequence (nt 1253-1350) whose deletion reduces splicing of pgRNA in Huh-7 
cells and HeLa-T4+ cells transfected with HBV sequences. However, PRE was also shown to 
contribute to pgRNA stability and repress HBV RNA splicing by the splicing factor PSF. 
This implies that a number of unknown RNA-binding and protein-protein interactions are 
necessary to enhance splicing. 
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Interestingly, a group of investigators tested a series of core protein mutants at the carboxy-
terminal sequences, which comprises a nucleic acid binding domain rich in arginine residues 
plus 3 serine phosphorylation sites, in transfected Huh-7 cells (Kock, Nassal et al. 2004).  
They found that replacement of all the serine residues, plus deletion of the 19C-terminal 
amino acid residues, gave rise to a nucleocapsid containing a 2-kb double-stranded DNA 
molecule derived from spliced pgRNA. Full-length pgRNA was associated with 
nucleocapsids but was sensitive to nuclease digestion, while encapsidated spliced RNA and 
3’ truncated RNA species were resistant to nuclease activity. This combination of mutations 
probably does not occur in vivo significantly, but this study highlighted the importance of the 
C-terminal portion of the core protein and its interaction with the pgRNA. This also suggests 
that additional host-viral factors may select for the production of defective viral particles. 
 
 
1.3.2.3    Production and distribution of splice variant DNA in cell cultures 
 
Human hepatoma cell lines Huh7 and HepG2 transfected with HBV genome have been the 
most popular cell models of viral replication and viral protein expression, and DNA 
synthesized by spliced RNA are regularly produced at high levels (up to 50% of total HBV 
DNA) (Abraham 2007). This could potentially complicate the analysis of HBV DNA 
synthesized in studies using these transfected cell cultures. More spliced RNA was observed 
when using the CMV promoter compared to the endogenous HBV promoter, and when P 
protein was supplied in trans versus in cis. Huh7 cells were noted to produce more splice 
variant DNA than HepG2 cells.  
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The relative quantity of the spliced products compared with the wild-type viral genome has 
been measured by densitometric scanning of the corresponding bands of the respective PCR 
products. Sommer et al. reported this signal intensity ratio of the wild-type and the 
predominant spliced genomes isolated from viral particles from the cytoplasm and the cell 
culture medium of  HepG2 and Huh-7 cells transfected with genotype D HBV. There was a  
surprisingly high proportion of the spliced genome in the cytoplasm (69%), but less in the 
medium (25%) (Sommer, van Bommel et al. 2000). The authors suggested that nucleocapsids 
containing wild-type length genomes are preferentially enveloped or released from the cells, 
although this had not been proven in vivo or duplicated. There is also concern about the use 
of densitometry of the final PCR product for quantification of the wid-type and spliced 
genome as there is a significant size difference (2 kb vs 3.2 kb) which may affect both PCR 
efficiency and band intensity, which the authors controlled by using defined mixtures of 
cloned genomes as templates. 
 
 
1.3.2.4    Possible effects on HBV viral replication and viral protein expression 
 
Rosmorduc et al. transfected the Huh-7 cell line with a singly spliced 2.2 kb-HBV DNA and 
demonstrated that the expression of the spliced species led to a marked intracellular 
accumulation of the major core protein (HBcAg) up to approximately 20-fold compared with 
the corresponding full-length HBV genome (Rosmorduc, Petit et al. 1995). There was also 
increased secretion of hepatitis e antigen (HBeAg). These results were confirmed by 
immunocytochemical analysis. As expected, there was no replicative product detected in the 
cells transfected with the spliced DNA alone on Southern blot analysis, but in the cells 
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cotransfected with spliced DNA and HBV polymerase plasmids, bands corresponding to 
single- and double-stranded spliced DNA were detected. 
 
Lin et al. amplified and cloned the 3.2 kb full-length HBV genome and the 2.2 kb spliced 
variant from liver tissues of hepatocellular carcinoma patients (Ni, Tian-Sheng et al. 2012). 
When full-length HBV DNA was co-transfected into HepG2 cells with the 2.2 kb spliced 
variant, the replication signal of the 3.2 kb HBV genome was increased 3-7 times, compared 
with transfection with the 3.2 kb genome alone, suggesting that this spliced variant could 
enhance the replication of the full-length HBV genome. This paper, published in a Chinese 
journal, contained reasonable details of the methodology and results. However it is interesting 
to note that the 2.2 kb splice variant used for cotransfection was a doubly-spliced genome 
unreported by earlier studies. This could be a local variant, but could affect the 
generalizability of the results. 
 
It was previously thought that only HBV pregenomic RNA  underwent splicing. However 
Hass et al. detected spliced pre-S2/S RNA in HBV transfected hepatoma cells, demonstrating 
that the S-transcript underwent splicing during replication of the full-length HBV genome 
(Hass, Hannoun et al. 2005). The same group also sequenced and functionally tested several 
full-length HBV clones from HBsAg-negative patients who developed viral reactivation, and 
identified a single G-A mutation within the S gene (position 458), which caused failure to 
express pre-S2/S mRNA and HBsAg. This mutation affected a 5’ splice site and prevented 
splicing of the pre-S2/S mRNA from position 458 to 1305. It reduced the pre-S2/S antigen 
expression but the posttranscriptional mechanism was uncertain. It was noted that the HBV 
clones obtained from these patients had reduced replication competence. 
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1.3.3   Studies of splice variants from human livers and sera infected with 
hepatitis B virus 
 
1.3.3.1    How frequent is the occurrence of hepatitis B virus splice variants in vivo? 
 
Evidence from PCR analysis of HBV DNA derived from chronically infected patients’ sera 
revealed that splice variants were highly prevalent in vivo - up to 96% in one series 
(Rosmorduc, Petit et al. 1995). Lin et al. also found a 2.2 kb splice variant present in all 
tumor and peri-tumor samples from 12 hepatocellular carcinoma patients studied (Ni, Tian-
Sheng et al. 2012). There were also reports demonstrating a higher proportion of the major 
spliced genome compared with the wild-type length genome in liver samples in some chronic 
hepatitis cases (Terre, Petit et al. 1991, Gunther, Sommer et al. 1997, Sommer, van Bommel 
et al. 2000). 
 
 
1.3.3.2    Does the hepatitis B spliced RNA translates into a novel protein? 
 
Soussan et al. (Soussan 2003, Sun, Hou et al. 2011) discovered a novel 10.4 kDa HBV 
protein encoded by a singly spliced HBV RNA in HBV-infected liver samples, which the 
investigators termed HBV splice-generated protein (HBSP). It was the result of fusion of a 
part of the viral polymerase and a new ORF that was created by the splicing event. This 
protein was made up of 93 amino acids, including the first 46 amino acids of the polymerase 
and 47 amino acids downstream from the splice site, corresponding to a new HBV amino 
acid sequence generated by the frame shift. This protein was detectable by Western blot 
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analysis of liver biopsy tissues from 4 out of 5 chronic HBV patients, but not from 2 hepatitis 
C-infected and 1 normal liver samples. 
 
Corresponding anti-HBSP antibodies were identified in 46% of sera samples from 125 
chronic HBV carriers (43% of whom were HBeAg positive) and 1% (1/84) of HBV negative 
healthy subjects (Soussan 2003). Concomitant expression of HBSP protein and anti-HBSP 
antibody was noted. There was a positive association between anti-HBSP antibody detection 
and presence of HBeAg, as well as higher HBV DNA. Multivariate analysis showed that the 
presence of anti-HBSP antibody was associated with viral replication, severity of fibrosis and 
elevated TNF-α secretion. 
 
In vitro studies by the same group showed that the ectopic expression of HBSP in HuH7-
transfected cells had no effect on viral DNA replication or transcription, except inducing cell 
apoptosis (Sun, Hou et al. 2011). Another recent study investigated the effect of transfecting 
a replicative HBV genome into HepG2 cells, which caused an extensive cytopathic effect 
(Lu, Tan et al. 2006). HBSP-induced caspase-dependent apoptosis was noted to play a major 
role in HBV-induced cell death. The presence of a Bcl-2 homology domain 3 was identified 
on HBSP by data mining. The exact biological significance of this is not known, but it 
challenges the well-established concept of HBV being a non-cytopathic virus that mediates 
liver cell injury only through the host immune response. 
 
A more recent paper explored the possibility of generating immunogenic peptides by the 
processing of an alternate reading frame (ARF)-generated HBSP in vivo (Mancini-Bourgine, 
Bayard et al. 2007). This 111-amino acid sequence was created from the fusion between the 
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first 46 residues of HBV polymerase and 65 amino acids encoded by the HBV ARF 
generated after the splicing of the HBV mRNA. The authors identified 2 HLA-A1-restricted 
peptides and 1 HLA-B7-restricted epitope following the immunization of human MHC class I 
transgenic mice with DNA vectors encoding HBSP. Multispecific HBSP-specific T-cell 
responses were also induced in peripheral blood mononuclear cells from 12 patients with 
chronic hepatitis B but not from 6 control patients using a set of overlapping peptides 
covering the HBSP sequence. This suggests that a “decoy-directing” immunity towards 
HBSP, which is not essential for HBV life cycle and may provide a mechanism for viral 
persistence in chronic infection.  
 
 
1.3.3.3    Is the production of splice variants important in acute hepatitis B infection? 
 
Only one clinical study has addressed the significance of splice variants in acute hepatitis B 
infection so far. Thirty-six patients with acute hepatitis, defined by 1) no previous history of 
liver or biliary disease; 2) no previous transfusions; 3) marked initial elevation of 
transaminase activity; and 4) high titers of anti-hepatitis B core protein IgM, were 
investigated for the presence of defective HBV DNA (a 2.2 kb splice variant) by PCR 
analysis (Rosmorduc, Petit et al. 1995). Of the 36 patients, complete HBV DNA was detected 
in 29 patients, 6 of whom progressed to chronic infection and 23 who recovered completely. 
Defective HBV DNA was detected in 100% of the 6 who developed chronic hepatitis B but 
only in 9% (2 out of 23 patients) of those who recovered completely. Using densitometric 
analysis, the authors estimated a 50-fold higher amount of defective HBV DNA in sera of 
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those patients with acute hepatitis who progressed to chronic hepatitis, as compared with 
those who recovered.  
 
The major criticism of this study is that anti-HB core IgM is known to be elevated in about 
33% of the chronic hepatitis B carriers who develop a flare (Li, Wang et al. 2011), so that 
some of the recruited cases may not actually be true acute hepatitis B. It would be interesting 
if the HBV DNA of those who did not progress to chronic hepatitis B were sequenced to see 
if the splice sites were conserved. 
 
 
1.3.3.4   How do splice variants affect the long-term clinical course of hepatitis B 
infected patients? 
 
The investigators in the above study (Rosmorduc, Petit et al. 1995) also  found the spliced 
HBV DNA in 27 out of 28 cases (96%) of chronic hepatitis B carriers. This observation of 
splice variant being associated with a chronic HBV infection was also reported by a number 
of other authors (Terre, Petit et al. 1991, Gunther, Sommer et al. 1997, Sommer, van Bommel 
et al. 2000), even though splicing of the HBV pgRNA appears not to be essential for viral 
replication in vitro (Su, Lai et al. 1989, Li, Xie et al. 2011).  
 
A recent analysis of complex HBV variants (species carrying deletions in the C gene and/or 
preS region and deletions/insertions in the core promoter) derived from sera and liver of a 
single immunosuppressed renal transplant recipient before and during cirrhosis, showed that 
accumulation of these complex variants was associated with development of cirrhosis 
(Marschenz, Endres et al. 2006). When transfected into hepatoma cell line Huh-7, the authors 
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identified altered phenotypes combining enhanced replication with defects in protein 
expression. The level of the dominating spliced RNA SP1 of the complex variants was also 
extremely reduced on northern blot analysis. 
 
Sheen et al (2007) looked for spliced HBV RNA (Sheen, Tsou et al. 2007) within liver 
biopsies from 32 consecutive patients from a single centre in Taiwan. 78.1% of the patients 
were HBeAg positive, and mean alanine aminotransferase (ALT) level was 324 U/L (range 
22-2246 U/L). Majority was of genotypes B and C. Three patients were superinfected by 
hepatitis C and two patients by hepatitis D infection. The singly spliced and unspliced HBV-
RNA was quantified by RT-PCR followed by Southern blot analysis. Multiple clinical, 
pathological and virological variables were analysed, of which histology activity index (HAI) 
and the levels of nuclear HBcAg expression were found to be two independent correlates of 
the expression of singly spliced HBV-RNA. Higher spliced /unspliced ratios were 
significantly associated with HAI score ≤6 and grade of nuclear HBcAg ≥2. The study 
population was probably heterogeneous and selected based on their respective indications for 
liver biopsies, hence the high mean ALT levels. Subgroup analysis was not presented. The 
hepatitis C and D coinfected individuals should not have been included in the analysis. 
 
 
1.3.3.5    HBV splice variants and lamivudine resistance mutations 
 
An important paper by Preiss et al. (Preiss, Littlejohn et al. 2008) compared the levels of 
defective viral DNA produced by RNA splicing in 285 HBV-infected individuals using 
quantitative PCR designed to detect the splice variant that produced HBSP. Interestingly the 
ratio of defective DNA was significantly lower in those infected with lamivudine resistant 
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forms of HBV (1.08% vs. 3.89%). In vitro transfection study using lamivudine resistance 
virus genome also produced reduced amounts of defective DNA. Mutations on the 
polymerase domain resulting in lamivudine resistance are distant and unlikely to directly 
affect the splice donor and acceptor sequence. The mechanism for the above observation is 
still not clear. One could speculate that patients with lamivudine resistance had higher HBV 
DNA levels and more likely to have active necroinflammatory activity, both of which may 
have a more direct impact on the splice variant production. 
 
 
1.4  Major unresolved issues 
 
Two major questions concerning HBV splice variants remained unanswered, namely:  
i) What is the biological importance of the splice variants?  
ii) Do they have any clinical significance? 
 
A study of the functional splice donor and acceptors sites by Gunther et al.(Gunther, Sommer 
et al. 1997) revealed a high level of conservation of these sites (8 out of 9) in all known HBV 
genotypes, which supports the biological importance of HBV splicing. The very high 
prevalence of splice variants isolated from sera and liver of chronic hepatitis B patients 
further argues for a significant role in the persistence of hepatitis B infection. 
 
Several hypothesis about the function of RNA splicing in HBV pathogenesis have been 
proposed. Several viruses synthesize defective interfering particles which contribute to 
persistent infection (Takkenberg, Terpstra et al. 2011). They may attenuate helper virus 
virulence by acting as inhibitors of virus multiplication, and modify the host immune 
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response to the virus. The recent functional analysis of complex HBV variants which 
demonstrated decreased HBV RNA splicing with progression into cirrhosis (implication of 
increased immune-mediated liver injury) supports the hypothesis of the immunomodulatory 
function of the splice variants (Marschenz, Endres et al. 2006). 
 
Marked intracellular accumulation of the HBcAg and increased secretion of HBeAg when 
splice variants were expressed have been described. There was also accumulation of RNA 
molecules coding for the X protein in splice variant transfected cells even though western 
blot analysis did not conclusively demonstrate the accumulation of X protein (Rosmorduc, 
Petit et al. 1995). X protein is known to transactivate a variety of viral and cellular genes, and 
is implicated in hepatocyte transformation and so may contribute to the observation of 
increased HBV multiplication in vitro and viral persistence in vivo. 
 
The identification of HBSP and anti-HBSP antibodies generated much interest as it provided 
the splice variant a “cDNA-like” function, and draw a parallel with the related duck HBV 
which produces a spliced mRNA which has been shown to be functionally important for viral 
replication in duck hepatocytes and ducks (You, Wu et al. 2011). However the cytopathic 
effect of the HBSP with the transfection of HBV genome has not been a feature of hepatitis B 
infection in vivo. The fact that more than one form of HBSPs (the original and the ARF-
generated) exists also raised concerns about the specific importance of these frame-shift 
generated proteins. The role of anti-HBSP antibodies as a marker for viral replication or 
severity of fibrosis requires more validation studies. The proposition of HBSP as an immune 
decoy will need to be explored further. 
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With only one study to date (Rosmorduc, Petit et al. 1995), the ability of the HBV spliced 
variant to predict chronicity at the time of acute hepatitis B infection has not been fully 
established. Larger studies, using more precise quantitative methods to evaluate the splice 
variant load, may be needed to clarify the issue. 
 
Despite its small genome size, the hepatitis B virus displays surprising complexity in its 
genotypic and phenotypic expressions, and high level of host-virus interactions. HBV RNA 
splicing adds another piece to the puzzle which has to be solved before we can understand the 
pathogenesis of chronic hepatitis B infection and find better prognostic tools and therapeutic 















Chapter 2: Materials and Methods 
 
The chapter contains the sample preparation and analysis protocols used repeatedly in various 
experiments carried out in the thesis. These standardized protocols were used in our 




2.1.1.   Biological materials 
 
Escherichia coli (JM109) (Gibco-BRL, Gaithersburg, USA); hepatoblastoma cell line 
(HepG2, ATCC HB 8065) (ATCC, Manassas VA, USA); HepG2.2.15 cell line (HepG2-
derived cell line, with stable HBV particle production) (Kuloglu, Kansu et al. 2010); 
hepatoma cell line (HuH7);fetal calf serum (FCS) (GIBCO BRL, Gaithersburg, USA; 
Invitrogen, Carlsbad, USA).  
 
 
2.1.2.   Chemicals, reagents and equipment 
 
All chemicals used were of either American Chemical Society (ACS) analytical grade, 
Molecular Biology grade or of the highest grade available commercially. The chemicals, 
reagents, kits and the equipment used in this thesis and their sources are listed in the 




2.1.3.    Subjects 
 
All chronic hepatitis B patients studied in this thesis were selected from a large cohort of 
long-term follow up hepatitis B patients at the University Digestive Clinic of the National 
University Hospital, Singapore.  
 
Chronic hepatitis B (CHB) was defined as a persistent seropositivity of HBsAg for at least 6 
months in the course of HBV infection. Only CHB patients who had previously consented for 
the use of their sera and liver tissue samples to be used for research purposes were included 
in the study. Blood for liver function, full blood count, and renal function were tested 
regularly during the patients’ follow-up. Viral markers were checked at 3 to 6 months during 
treatment.Patients with no treatment were checked for viral markers regularly at intervals of 6 
month to 1 year.  
 
The biochemical tests and complete blood cell counts were measured using routine automated 
techniques. All patients included in this thesis were negative for antibodies to hepatitis C 
virus (QuantiplexTM 2.0 Assay, Chiron Diagnostics Ltd, Halstead, USA) and human 
immune deficiency virus (Abbott Laboratories, North Chicago, USA). HBsAg, HBeAg, anti-
HBe and anti-HBswere measured using microparticle enzyme immunoassay (MEIA, Abbott 
Laboratories,North Chicago, USA) and HBV DNA by a commercial real-time PCR assay 
(Artus GmbH, Frankfurt, Germany). 
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The serum samples of all patients were prepared from the whole blood sample in plain tubes. 
The blood samples were centrifuged at 2500 × g, at room temperature for 10 minutes and the 
sera were aliquoted and stored at -80 ºC until use. 
 
This study was approved by the Domain Specific Review Board (DSRB) of the National 
Healthcare Group (Singapore). 
 
 
2.2.   HBV DNA Preparation and Analysis 
 
2.2.1.   DNA extraction 
 
Total DNA (used in Chapter 3) including viral DNA was extracted from each serum sample 
using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. 
 
Briefly, 200 µl of buffer AL was mixed with 200 µl of serum sample and 20 µl proteinase K 
(20 µg/µl) before being incubated at 56 ºC for 10 min. The mixture was mixed well with 200 
µl of ethanol and applied to the QIAamp spin column which was then centrifuged at 6000 × g 
for 1 min. The column was washed once with 500 µl buffer AW1 and 500 µl buffer AW2 
separately in order to remove any residual contaminants. The DNA was eluted with 200 µl of 
sterile distilled water and stored at -20 ºC until use. 
 
For core-associated HBV DNA extraction (used in chapter 4 and 5), the cells were 
washed twice with PBS and lysed in 500 µl of lysis buffer (50 mM Tris–HCl, pH 7.4, 1 mM 
! 50!
EDTA, 1% Nonidet P-40) 60-mm diameter petri dish for 15 min. Nuclei were pelleted by 
centrifugation for 1 min at 14,000 rpm (Eppendorf centrifuge). The supernatant was adjusted 
to 10 mM MgCl2 and treated with 100 µg/ml of DNase I (Roche Diagnostics) for 30 min at 
37°C. The reaction was stopped by the addition of EDTA to a final concentration of 25 mM 




2.2.2.   HBV Genotyping 
 
A 479-bp fragment in the pre-S region of HBV was amplified for genotyping using primers 
designed by Lindh et al.: forward primer from nt. 2828-2848, 5’-TCACCA TAT TCT TGG 
GAA CAA GA-3’ and reverse primer (nt. 80-61), 5’-TTC CTGAAC TGG AGC CAC CA-3’ 
(Kwon and Lok 2011). 
 
PCR reaction mixtures were prepared in a total volume of 50 µl, containing 5 µl of extracted 
serum DNA template, 5 µl of 10 × PCR buffer, 1 µl of MgCl2 (25mM), 0.2mM of each 
dNTP, 0.8 µM of each primer and 2.0 units of Taq DNA polymerase (HotStar, Qiagen, 
Hilden, Germany). The enzyme was activated by heating up at 95 ºC for 15min followed by 
35 cycles DNA denaturation at 94 ºC for 1min, annealing of primers at 53 ºC for 1 min, and 
extension at 72 ºC for 1 min. The last cycle was followed by a final extension step at 72 ºC 
for 7 min. PCR was performed in a T3 Thermocycler (Whatman Biometra, Maidstone, UK). 
10 µl of the PCR product was mixed with 1.5 µl of 10 × restriction enzyme buffer, 3 µl of 
distilled water and 0.5 µl (5 U) of either Ava II or Dpn II, and the reaction was incubated at 
37 ºC for 3 hours before electrophoresis on a composite gel containing 2% NuSieve agarose 
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(FMC BioProducts, Rockland, USA) and 1% of standard agarose. A control reaction without 
restriction enzyme for each sample was run in parallel with the enzyme-treated samples. 
DNA was visualized by ethidium bromide staining. 
 
 
2.2.3.   HBV DNA Quantitation 
 
Real-time PCR was conducted using the ABI Prism 7000 sequence detection system (Applied 
Biosystems, Foster City, USA). Primers were designed with Primer Express 2.0 software 
(Applied Biosystems). Amplicons of P-188, S-222, S114 and C-140 were detected by the 
SyBr Green assay using Quantitect SYBR Green PCR Master Mix (Qiagen, Hilden, 
Germany). These primers were designed to amplify the different regions of the viral genome 
that were either always deleted by the HBV pgRNA splicing (S-222 and S-114), or were not 
affected by splicing process (P-188 and C-140). Specificity of primers was confirmed by 
BLAST search. PCR reaction were carried out in duplicate for each biological sample. Primer 
sequences are detailed in Table  2.1. 
 
 
2.2.4.   Cloning and sequencing 
 
Cloning and sequencing of the HBV post-transcriptional regulatory element (PRE) (section 
3.2.6.2) was carried out to look for any specific mutation(s) that may influence the production 
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PCR was carried out for all samples using the following PCR primers flanking the PRE 
region: forward, 5’ GCC AAG TGT TTG CTG ACG CAA ‘3; reverse, 5’ CAA TTT ATG 
CCT ACA GCC TCC ‘3. The PCR reaction mixtures were prepared in a total volume of 25 
µl containing 2.5 µl of DNA template, 2.5 µl of 10 × PCR buffer with MgCl2 (25 mM), 0.2 
mM of each dNTP, 0.8 µM of each primer and 1.0 units of DYNAzyme Taq DNA 
polymerase. 
 
The reaction was carried out for 40 cycles. The initial activation was at 95ºC for 3 min. Each 
cycle included DNA denaturation at 94ºC for 1min, annealing of primers at 55ºC for 30 sec, 
and extension at 72ºC for 1minute and 30 seconds. The last cycle was followed by a final 
extension step at 72ºC for 10 min. A 622-bp fragment containing the whole PRE (nt. 1217-
1582) was amplified. The PCR product was extracted and purified from 1.5% TAE agarose 
gel using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. 
 
The purified PCR product was cloned into pGEM-T vector (Promega, Madison, USA) in a 
3:1 molar ratio of insert: vector. Ligation reaction 10 µl each contained 5 µl of 2 x Rapid 
ligation buffer, 50 ng of pGEM-T, 32 ng of PCR product, 3 Weiss units of T4 DNA ligase 
and sterile distilled H2O. The reactions were incubated at 4 ºC overnight before 
transformation. 
 
3 ml of LB broth was inoculated with 100 µl of bacterial culture stock ( E.coli JM 109) and 
grown overnight at 37ºC and 200 rpm in a shaker incubator. 300 µl of the overnight culture 
was inoculated in 10 ml LB broth and grown at 37ºC for 2 hours so as to obtain bacterial cells 
in the log phase of cell growth. The cells were spun down at 2500 x g, 4 ºC for 10 min. The 
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supernatant was discarded and the pellet was resuspended in 5 ml of cold 0.1 M CaCl2, 
incubated on ice for 15 min and then centrifuged 2500 x g, 4ºC for 10 min. The supernatant 
was discarded and 0.5 ml of cold 0.1M CaCl2 was added to resuspend the cells, which were 
left on ice for at least 15 min before use. 
 
50 µl of the cell resuspension (competent cells) was mixed with 5 µl of DNA/pGEM-T 
ligation mixture in a microcentrifuge tube and incubated on ice for 30 min. The cells were 
heat shocked at 42ºC for 2 min and then immediately chilled on ice for 1 min. Pre-warmed 
LB broth (250 µl) was added and the mixture was incubated at 37ºC, 200 rpm shaking for 1 
hour. The mixture 100 µl were plated on a pre-warmed LB/ampicillin (100 µg/ml) agar plate 
with X-Gal (80 µg/ml) and IPTG (0.5 mM). Three plates were used for each sample. The 
plates were inverted and incubated overnight at 37 ºC. 
 
At least 20 single white colonies were picked up randomly from the 3 plates of each sample 
the following day for screening of positive clones. Colonies were grown in 3 ml of LB 
broth/ampicillin (100 µg/ml) overnight at 37ºC with shaking at 200 rpm. 
 
Alkaline lysis miniprep of plasmid DNA was carried out with 1.5 ml of the overnight culture 
using Wizard Plus Minipreps DNA purification System (Promega, Madison, USA) as 
manufacturer’s instructions. In brief, 1.5 ml of the overnight grown culture from each colony 
was pelleted by centrifugation at 20,000 × g for 5 min and the cell pellet was resuspended 
with 250 µl of re-suspension solution. The cells were then lyzed with 250 µl of lysis solution 
together with addition of 10 µl of alkaline phosphatase to remove any protein contaminants 
by being incubated at room temperature for 5 min. The cell lysate was mixed with 350 µl of 
neutralization buffer before being centrifuged at 20,000 × g for 15 min. The supernatant from 
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each tube was transferred to Wizard spin column and spun at 20,000 × g for 1 min. The 
column was washed with washing solution twice and the DNA was eluted with 40 µl of 
nuclease free distilled H2O. 
At least 20 positive clones per time point sample of each patient were randomly selected and 
sequenced. Plasmid DNAs of selected clones were used as the template in cycle sequencing 
reactions. The sequencing primers were the flanking sequence of the insert on the pGEM-T 
vector: forward-pGEM-f, 5’-TTG TAA TA CGA CTC AC TA-3’ and reverse-pGEM-r, 5’-
GGA TAA CAA TTT CAC ACA-3’. The cycle sequencing reaction was set up as described 
in Section 2.2.3.1. 
 
For full-length HBV genome cloning (3.2kb), the Topo XL PCR Cloning Kit (Invitrogen, 
Carlsbad, USA) was used according to the manufacturer’s instruction. In brief, 5 µL of 
TOPO Cloning reaction was set up, containing 4 µL gel-purified long PCR product and 1 µL 
pCR-XL-TOPO® vector. After incubation for 5 minutes in room temperature, 1 µL of the 6X 
TOPO® Cloning Stop Solution is added  and place on ice. 
 
Chemical transformation was carried out by adding 2 µL of the TOPO® Cloning reaction 
into a vial of One Shot® cells and mix gently. After incubate on ice for 30 minutes, the cells 
underwent heat-shock for 30 seconds at 42°C. The mixture was shaked horizontally at 225 
rpm at 37°C for 1 hour, then spread on a prewarmed plate. Incubate plates overnight at 37°C. 
Clones were screened by miniprep and digested with restriction enzymes SapI. The inserts in 
positive clones were confirmed by sequencing (Sun, Qin et al. 2010) and the corresponding 




2.2.5.    DNA Sequencing 
 
The purified PCR product was used as template of cycle sequencing reaction and the 
sequencing primers were same as those used for PCR. The DNA sequencing was performed 
using BigDye Terminator Cycle Sequencing Kit version 3.0 (Applied Biosystems, Foster 
City, USA) according to the manufacturer’s protocol. 
 
In brief, each 10 µl of sequencing reaction contained 4 µl Big Dye terminator reaction mix, 2 
µl (10-30 ng/µl) PCR product, 1 µl (3.2 pmol) forward or reverse primer and sterile distilled 
H2O. Cycle sequencing was conducted under the conditions, 25 cycles of 96ºC for 30 
seconds, 50ºC for 15 seconds and 60ºC for 4 min, and a final incubation at 4ºC. The cycle 
sequencing products were mixed with 2 µl of 3 M NaOAc, pH 5.6 and 50 µl of absolute 
ethanol and incubated at room temperature for at least 15 min. The mixture was centrifuged 
at 20,000 × g for 20 min. The DNA pellet was rinsed with 250 µl of 70% ethanol before 
being vacuum dried for 10 min. 
 
The dried DNA pellet was dissolved in 4 µl of loading dye with deionized formamide and 
EDTA (25 mM, pH 8.0)/ Blue dextran (50 mg/ml) at 5:1. The mixture was mixed well and 
denatured at 95ºC for 2 min before being chilled on ice. The ready-to-load template was kept 
in the dark before loading. Products were resolved on a 4% of denaturing-polyacrylamide 
sequencing gel onan ABI PrismTM 377 automated DNA sequencer (Applied Biosystems, 
Foster City, USA).  
 
Sequencing electrophoresis was performed at 1.68 kV and 51ºC for 7 hours. The signals were 
collected by the ABI PrismTM 377 Data Collection software version 1.1 and analyzed by the 
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ABI PrismTM 377 XL Sequencing analysis software version 3.4.1 (Applied Biosystems, 
Foster City, USA).  
 
2.2.6.    Phylogenetic tree analysis (section 3.2.6.2) 
 
Sequences were aligned using the program SeqMan Pro version 7.1.0 (DNASTAR) and 
BioEdit version 5.07 (Tom Hall, North Carolina State University, Department of 
Microbiology). Distances between pairs of sequences were calculated based on Kimura two-
parameter method. Phylogenetic trees were created by neighbour-joining method. All 




2.3  RNA preparation and analysis  
 
2.3.1    RNA extraction 
The total RNA from the cell culture or liver tissue was extracted using RNeasy Mini kit using 
Spin Technology (Qiagen, Hilden, Germany) according to the manufacturer’s instruction. 
The whole process was carried out in a dedicated RNA working area thoroughly 
decontaminated with RNaseZAP (Life Technologies, Singapore). 
 
In brief, up to 1 x 107 cells grown in a monolayer were lysed directly in the culture plate or 
trypsinized and collected as a pellot prior to lysis. The cells were disrupted by adding Buffer 
RLT.  The lysate was then homogenized by transferrin it directly into a QIAshredder spin 
column and centrifuge for 2 minutes at full speed. The RNA was precipitated by adding 70% 
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ethanol and the sample was transferred into an RNeasy spin column and centrifuged for 10 
sec at 10000 x g. The spin column was washed 3 times with wash buffers and the RNA eluted 
in 50 µl RNase-free water.  
 
The concentration and quality of the extrated RNA (A260/A280 ratio) was analysed using the 




2.3.2    Reverse transcription 
 
The RNA sample was treated with 100 µg/ml of DNase I (Roche, Singapore) for 30 min at 
37°C before performing reverse transcription. The reverse transcription was performed using 
the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Carlsbad, USA) according 
to the manufacturer’s instruction. 
 
In brief, 0.1 pg to 5 µg of total RNA was annealed to Primer (50 µM oligo(dT)20 in a thermal 
cycler at 65°C for 5 minutes. After that, the First-Strand Reaction Mix 10 µl SuperScript™ 
III/RNaseOUT™ Enzyme Mix was added for reverse transcriptase reaction for 50 minutes at 
50°C. The reaction was terminated at 85°C for 5 minutes. The cDNA was chilled and stored 
for subsequent analysis. 
 
 
2.4    Protein Analysis 
 
! 59!
2.4.1  HBsAg and HBeAg ELISA Assay  
 
The HBsAg immunoassay was carried out using the Monolisa HBsAg ULTRA kit by (Bio-
Rad, Singapore). In brief, the control sera and samples was distributed into the wells of the 
microplate (coated with mouse monoclonal anti-HBs antibodies), followed by a red coloured 
conjugate containing mouse monoclonal anti-HBs antibodies and goat polyclonal anti-HBs 
antibodies bound to the peroxidase.  
 
After incubation at 37°C during one hour and half the unbound conjugate is removed by 
washing, and  Substrate solution, containing citric acid and sodium acetate solution pH 4.0, 
0.015% H2O2 and 4% DMSO. After 30 minutes incubation in presence of the substrate in the 
dark and at room temperature, the presence of the complexed conjugate was shown by a 
change of colour. The reaction was stopped the addition of sulphuric acid solution. The 
optical densities were read at 450/620-700 nm and the results were read against linear phase 
of a standard curve.  
 
The HBeAg immunoassay was carried out using the Monolisa HBe Ag-Ab Plus kit (Bio-Rad, 




2.4.2    Protein extraction 
 
Protein was extracted from cells by aspiration of medium, wash twice with 1 x PBS 
(Phosphate Buffered Saline) before addition of ice-cold lysis buffer [150 mM NaCl, 1% NP-
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40 (nonyl phenoxypolyethoxylethanol), 50 mM Tris pH 8.0] with compete protease inhibitor 
cocktail tablets (Roche, Singapore). 100 ul of the lysis buffered was added to adherent cells 
grown in 6-well plates. Cells were scraped and incubated on ice for 30 minutes, with 
vortexing at 10 minutes interval, before centrifugation at 13,000 rpm for 10 minutes at 4 °C. 
The lysate, which included  the cytoplasmic and viral proteins, was removed and adjusted to 
1 x Laemmli loading buffer using 4 x stock solution for use, or stored at -80 °C for future use. 
 
 
2.4.3 Polyacrylamide gel electrophoresis 
(Sodium dodecylsulphate (SDS) PAGE) 
 
2.4.3.1  Sample preparation 
 
Protein samples were adjusted to 1x  Laemmli loading buffer [10 mM Tri-HCL pH 6.8, 10% 
(v/v) glycerol, 2% (w/v) SDS, 1% 9v/v) β–mercaptoethanol and 0.01% (w/v) bromophenol 
blue], heat at 95°C for 5 minutes, before loading. 
 
2.4.3.2  Electrophoresis 
 
SDS PAGE was conducted following standard protocols (Laemmli, 1970). Acrylamide gels 
were prepared on the same day of the electrophoresis. The resolving portion of the gel 
contained 375 mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 12% (W/v) acrylamide and 0.4% (w/v) 
bisacrylamide. The stacking portion contained 125 mM Tris-HCl pH 6.8, 0.1% SDS, 
4%(w/v) acrylamide and 0.13% (w/v) bisacrylamide. Gels were polymerised by addition of 
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0.1% (resolving) or 0.3% (stacking) (v/v) N,N,N,N’-tetramethylethylenediamine (TEMED) 
and 0.1% (resolving) or -.05% (stacking) (w/v) ammonium persulphate (APS). 
 
Protein samples were loaded and gels run at 100 V in Laemmli running buffer [25mM Tris, 
192 mM glycine, 0.1% (w/v) SDS] and transferred to a cellulose membrane ( Merk Millipore, 
Billerica, USA) for immunoblotting. 
 
 
2.4.4    Western blotting 
 
2.4.4.1   Protein transfer 
 
Proteins were transferred in a transfer sandwich from PAGE gels to membrane in 0.5x 
Laemmli running buffer [12.5 mM Tris, 96 mM glycine, 0.05% (w/v) SDS] containing 10% 
methanol. Transfer was induced at 100V for 1 hour in a cold room, with continuous stirring 
of the transfer buffer. 
 
2.4.4.2   Ponceau staining 
 
Immediately after transfer, even transfer of proteins to the membrane was verified by staining 
with Ponceau S solution [0.4% (w/v) Ponceau S, 5% (v/v) acetic acid] for 2-3 minutes and 
de-staining with methanol, and then the membranes were air-dried for photo record. 
 
2.4.4.3   Immunoblotting 
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Membranes were probed with antibodies using the dry-block method. Dried membranes were 
place in blocking buffer, TBS-Tween [5% (w/v) skimmed mild power, TBS (Tris-buffered 
saline, 0.1% (v/v) Tween-20] for 1 hour at room temperature. After that the membranes were 
incubated with primary antibody (see Table 2.2 for working dilutions) in blocking buffers, 
then incubate overnight in cold room with constant gentle rocking. 
  
The following day, the membranes were washed three times for 10 minutes with TBS-Tween, 
incubate for 1 hour with HRP-conjugated secondary antibody diluted in blocking buffer and 
washed three times again. 
 
Antibody binding was detected by enhanced chemiluminescence using the SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, USA). Membranes were 
incubated in the working solution for 5 minutes and exposed to X-ray film (Kodak) to 
visualize the signal. 
 
 
2.5 Cell culture transfection 
 
HuH7, HepG2 and HepG2.2.15 cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % (v/v) foetal calf serum (FCS) and 2mM glutamine, 
maintained at 37 ºC and 5 % CO2. Cells were grown to confluence before splitting 1:3 – 1:5 
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2.5.1    Transient DNA transfection into hepatoma cell line 
 
Aseptic techniques were used all the time for cell culture and bacterial work to avoid 
contamination. Linear HBV monomer was released from the vector by SapI digestion (New 
England Biolab, Singapore) and transfected into the Huh7 or HepG2 cell line.  The cells were 
seeded into 6-well plates 24 hours earlier, 2 x 105 cells per well, and grown at 37 °C and 5% 
CO2 to recover for 24 hours before the transfection was carried out.  
 
Effectene Transfection Reagent (Qiagen, Hilden, Germany) Protocol.   Briefly, 0.4 ug of 
DNA was condensed by interaction with the Enhancer in a defined buffer system to form the 
Effectene–DNA complex. Effectene reagent was then added to the condensed DNA in a ratio 
of 1: 25 to produce a condensed Effectene–DNA complexes, which spontaneously formed 
micelle structures. The Effectene–DNA complexes were mixed by vortexing for 10 sec. The 
tube was incubated at room temperature for 10 min to allow transfection-complex formation, 
which was then added directly to the cells. ApaI- and BamHI-digested vector pGEM-t DNA 
was used as the mock transfection control. The pSEAP2-Control vector was co-transfected, to 
be used as the internal control for transfection efficiency.  
 
After 24 hours, the medium containing the Effectene-DNA complexes were removed and 
changed into fresh DMEM medium. The dish was gently swirled after addition of the 
transfection complex and then incubated at 37 °C and 5% CO2 for another 48 hours. The 
medium of the transfected cells were collected and stored at -20°C until use for the HBsAg 





2.5.2    SEAP Chemiluminescence Assay 
 
In order to normalize the transient transfection efficiency,  the cell culture medium from 
transfected cells was analysed for the secreted alkaline phosphatase (SEAP)  (Great 
EscAPeTM SEAP Chemiluminescence Kit 2.0, Clontech, Singapore) between 48 to 72 hours 
after transfection.  
 
25µl of cell culture medium was transferred from transfected cells or mock transfected cells 
to a 96-well microtiter plate/ PCR tubes. 1X dilution buffer was prepared by diluting with 
ddH2O. The SEAP Substrate Solution was equilibrated to room temperature. 75µl of 1X 
Dilution Buffer was added to each sample in the 96-well microtiter plate. The plate was 
sealed with adhesive aluminum foil and incubated for 30 min at 65°C using a heat block. The 
samples were cooled on ice for 2–3 min, then equilibrate to room temperature. 100µl of 
SEAP Substrate Solution was added to each sample and incubated for 30 min at room 
temperature before reading. A 96-well plate reader luminometer (TECAN GENios machine, 




2.6   Statistical analysis 
The significance of the differences between two means was assayed using one way analysis 
of variance (ANOVA) for normal distributed data, or Mann Whitney U test comparing 
between groups and Wilcoxon’s signed rank test comparing between time points for the non-
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normal distributed data. Frequency variables were tested by a Fisher’s exact test. In all tests, 
























Chapter 3: HBV splice variant levels fluctuate with disease 
progression and with treatment. 
 
3.1  Introduction 
 
Previous work by Rosmorduc (Rosmorduc, Petit et al. 1995) and others, showed that HBV 
splice variants are highly prevalent amongst chronically infected patients. Our initial 
hypothesis was that the proportions of HBV splice variants may vary with time in the same 
patient, as he/she progressed through the different phases of the natural history of the 
infection. This may reveal the actual physiological role of HBV RNA splicing. For instance, 
if the splice variants has an immunomodulatory role and contribute to  immunotolerance, as 
some researchers suggested (Mancini-Bourgine, Bayard et al. 2007), one would expect that 
the transition from the immunotolerant phase to immunoactive phase may involve a fall in the 
proportions of the HBV splice variants. An accurate method to identify and quantify the ratio 
of the spliced variant to the wild-type viral genome is therefore needed. 
 
 
3.1.1  Identification of HBV splice variants in liver and serum samples 
 
HBV splice variants were previously identified by performing polymerase chain reaction 
using flanking primers across the splice donor and acceptor sites, or performing a full-length 
amplification of the viral genome. The splice variants were identified as distinct bands 
approximately 1.2 kb smaller than the wild-type viral DNA/RNA (Figure 3.1). 
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 P1 / P2 
Figure 3.1 Diagrammatic representation of the HBV genome coding regions, in 
relation to the 4 most common splice sites.  
 
The primers used for PCR reaction was labeled below. P1/P2: For amplification of the full-
lenth (3.2 kb) viral genome; P3/P4: For amplication around the splice regions, which allowed 
more specific identification of the spliced products (Sommer, van Bommel et al. 2000). 
 
 
Figure 3.2A  Gel electrophoretic analysis of HBV genomes derived from human liver 
tissue (Patients 1-5). Viral DNA isolated from human liver tissue (approximately 3-5mg) 
were amplified with primer pair P1/P2 for 40 cycles, separated in an agarose gel, and 
P1 / P2!




(A) Primers P1 / P2! (B) Primers P3 / P4!
Validation of Assay
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stained by ethidium bromide. The wild-type (WT) full-length HBV DNA was 3.2 kb and the 
spliced (SP) DNA was 2 kb. 
 
 
Figure 3.2B  Gel electrophoretic analysis of HBV genomes derived from human liver 
tissue (Patients 6-8 in lanes 1-3 respectively), amplified with primer pair P3/P4. The 
wild-type (WT) full-length HBV DNA was 2 kb and the spliced (SP) DNA was 800 bp. Note 
that in some patients, the WT was predominant (patients 6 & 7), in others, the SP was 











(A) Primers P1 / P2! (B) Primers P3 / P4!
Validation of Assay!
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This method was often combined with densitometry of the resultant bands to generate an 
estimate of the splice variant/wild-type RNA/DNA ratio (Sheen, Tsou et al. 2007). However 
the limitation to this method when it was applied to human samples was that many 
chronically infected patients had lower viral loads, and hence high amplification cycle 
numbers were needed to visualise the PCR products, which prevented reliable template 
quantification by densitometry.  
 
 
3.1.2  Developing a real-time PCR method to quantify the HBV splice 
variant DNA 
 
With the development of real-time PCR assay for the quantification of DNA, precise and 
consistent measurements of the DNA templates as low as 102 copies/ml became possible. We 
designed a set of SYBR green-based quantitative PCR assay using 4 primer sets specific for 
either genomic-length HBV or the splice variant HBV DNA. This qPCR primers (C-140, P-
188, S-222 and S-114, sequence as described in Table 2.1) were designed after choosing 
regions of high conservation both between and within HBV genotypes. Theses were then 
optimized and tested with the help of our collaborator in the Experimental Therapeutics 
Centre, Dr Masafumi Inoue. Aiming to detect all the forms of HBV splice variants reported 
so far (see Figure 1.11), the primer sets C-140 and P-188 primed DNA synthesis away from 
all reported splice region, while S-222 and S-114 primed DNA synthesis within the intron 




Figure 3.3  The HBV genome map with the coding region, the splice region and the 







Figure 3.4 The amplification plot of the same standards using different primer sets 
for the splice variant quantification.  
 
The standards containing 101, 102, 103, 104, 106 and 108 copes/ml of HBV DNA derived from 
a genotype C full-length HBV genome cloned into E. coli plasmid, extracted and serially 
diluted to the required concentration. The performance of each primer sets were optimised to 
produce similar signals as shown in Figure 3.4, with the correlation of variations of under 





HBV Cloned Vector Standards
y = -3.2487x + 35.091
R2 = 0.9981
y = -3.3809x + 36.639
R2 = 0.9994
y = -3.3884x + 36.196
R2 = 0.9975
y = -3.404x + 36.283
R2 = 0.9952
































)Linear (HBV P-188, Ct
)Linear (HBV S-114, Ct
)Linear (HBV X-134, Ct
)Linear (HBV S-222, Ct
)Linear (HBV C-140, Ct
! 73!
In brief, twenty-five microliter reactions, consisting of 2 uL sample, 100 pM of each primer, 
were analyzed using SYBR Green I detection chemistry, with an ABI- Prism 7000 sequence 
detection system (Applied Biosys- tems, Foster City, CA). Samples were quantified with a 
standard curve constructed from plasmid containing a full-length HBV genome cloned from a 
genotype C virus. Quantification above 250 wild-type copies per well was accepted as valid. 
Optimization reactions showed no non-specific amplification of wild-type plasmid with 
splice primers (intron region) when spiked with less than 200 plasmid copies per well. Intra-
assay coefficient of variation was determined to be less than 20%. The quantity of the splice 
variant DNA in the serum-derived DNA was determined by subtracting the amount of full-
length HBV DNA (average of S-222 and S-114 qPCR readings) from the total HBV DNA 
(average of C-140 and P-188 qPCR readings). The relative abundance of the splice variant 
DNA (% splice DNA) in the serum-derived DNA was determined by dividing the amount of 
spliced DNA by the total HBV DNA and multiplying by 100.  
 
Based on the review of our lab’s data on HBV quasispecies earlier (Lim, Cheng et al. 2007), 
at least 5% of each primer sites are subjected to one or more mutations due to the presence of 
viral quasispecies, even at the most conserved regions. In order to minimize the effect of 
these mutations, we chose to use the average of 2 primer set pairs to determine the quantity of 




Figure 3.5 Correlation of total HBV DNA measurement using Amplicor and new 























Correlation is significant at the .01 level (2-tailed).**. 
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The total HBV DNA measured by our primer sets correlated well with the Cobas Amplicor 
measurement (Spearman correlation coefficient = 0.889, P<0.001) on the same samples 
(Figure 3.5). 
 
3.2  Results  
 
3.2.1  Patient and sample selection 
 
A cohort of 19 Singapore patients with chronic hepatitis B and hepatocellular carcinoma 
undergoing hepatectomy was included in this study. 12 patients were positive for HBeAg, 7 
were HBeAg negative. 10 patients had HBV genotype C and 9 had HBV genotype B. None 
were on antiviral therapy at the time of surgery. Sera and non-tumour involved tissue were 
collected on the same day of their liver resection, and were stored at -70 degree Celcius 
immediately until they were selected for analysis.  
 
DNA extraction was carried out using QIAmp Blood Mini Kit (Qiagen, Hilden, Germany) 
serum and tissue protocol as detailed in section 2.2.1.1. 
 
 
3.2.2  The proportions of HBV splice variants in the serum correlate with 
their proportions in the liver tissue 
 
Before we can proceed to carry out serial quantification of HBV splice variants, one 
important question to address was whether the changes in the quantity of splice variant DNA 
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measured in the serum would be representative of its production in the liver. In a series of in 
vitro transfection experiments using hepatoma cell lines, Sommer et al (2000) demonstrated 
that there was higher percentage of intracellular splice variants than that in the culture 
medium at 48 hours after transfection. The authors suggested that there may be reduced 
export of the spliced viral particles out of the hepatocytes (Sommer, van Bommel et al. 2000). 
However there was no evidence that there was any difference between the envelope of these 
defective viral particles and the wild-type virus that could account for this selective excretion. 
 
We examined the 19 patients’ paired serum and liver samples using the qPCR assay designed 
to measure the total and spliced HBV DNA. The mean proportion of spliced HBV virus 
genomes was 17% in liver tissue (range 0% to 56%) and 21.9% in serum (range 0% to 
85.3%).  
There were significant correlations between liver and serum levels of both total HBV DNA 
(Pearson correlation coefficient=0.522, P=0.015) (Figure 3.6) and the proportions of spliced 
virus genome (Spearman correlation coefficient=0.586, P=0.008) (Figure 3.7). The 
proportions of spliced viral DNA levels in serum were not lower in the sera compared with 
that in the corresponding liver tissue, which differed from the results of the in vitro study 









Figure 3.7  Liver vs serum: Percentage of spliced HBV DNA. 
4 patients with undetectable 
spliced DNA in liver and serum 
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3.2.3  Analysis of the HBV splice variant DNA by sequencing 
 
The splice variants was also analysed by carrying out sequencing across the intron region. 
The HBV genome from the total DNA extracted from the liver tissue of the 19 patients 
(selected in section 3.2.1) was amplified using primers P1/P2. The spliced HBV DNA (2 kb) 
was gel-extracted, purified and analysed by Sanger’s method as discussed in Chapter 2, using 
the splice site flanking primers SP1-SP2 (Table 2.1). 
 
The sequencing data was analysed using the software Megalign, with a full-length HBV 











Figure 3.8A  Sequence alignment of HBV splice variants from liver-derived DNA of 19 
HBV patients. The last sequence is a full-length (3.2 kb) genotype C HBV genome. Due to 
the wide gap (1.2 kb) across the intron, only both ends of the splice sites were presented. The 
splice variant with type 6 splice pattern was labeled. 
 
 
Figure 3.8B  Diagrammatic genome map of Type 1 and Type 6 splice variants. 
The majority of the spliced HBV DNA in our cohort had Type 1 pattern (Figure 1.11 and 
Figure 3.8). However one single patient has a predominant Type 6 pattern, utilising a 5’ 
splice splice donor site 24 bp further downstream (Gunther et al. 1997). 
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3.2.4  The proportions of HBV splice variants changes at different stages of 
chronic hepatitis B infection 
 
We conducted a pilot study looking at five long-term patients who had serum collected at 
various time points of their chronic hepatitis B (CHB) infection, stored at -70 degree Celcius. 
The total HBV DNA was extracted and analysed using the qPCR assay for total/spliced HBV 





Figure 3.9  Measurement of serum total HBV DNA, percentage of splice variants and  
ALT levels at major clinical timepoints of in the natural history (no antiviral therapy) 
of 5 patients with chronic hepatitis B infection. The purple bar showed the total HBV DNA 
(spliced + wild-type) and the blue bar showed the spliced DNA level in the serum as detected 
by qPCR assay. Serum at some of the time points were not available for each of the patients. 
 
There was suggestion of an increase in the proportion of the HBV splice variants before the 
time of HBeAg seroconversion which declined after HBeAg seroconversion (Patients 1-3). 
At the time of HBeAg negative reactivation (defined as an increase in HBV DNA by >2 log 
copies/ml from the nadir, followed by ALT elevation), the splice variant levels also appear to 
increase for these patients (patients 1 and 2, patient in figure 3.10). 
 
We also reviewed the result from a hepatitis B patient who received lamivudine and had 
HBeAg serconversion, which subsequently reverted. He further developed virological 





Table 3.10   The ALT, Total and spliced HBV DNA profile of a patient who was 
treated with lamivudine and underwent HBeAg seroconversion and reversion.  
 
There was an increase in the HBV spliced genome proportion just before HBeAg 
seroconversion, although there may be a possible effect of the lamivudine treatment. 
However at the time of HBeAg reversion and viral breakthrough while on lamivudine, the 
proportion of spliced variants remain high (Table 3.10). 
 
 
3.2.5  The proportions of HBV splice variant rose during immunoactive 
phase, and peaked just before HBe-seroconversion 
 
Building upon preliminary finding that the proportions of HBV splice variants changes 
around the time of HBe-seroconversion, we soughted another cohort of patients with serial 
sera collected before and after their HBe-seroconversion event. 
 
 
3.2.5.1  Patient selection 
 
We were able to identify 13 chronic HBV infected patients follow-up at the National 
University Hospital who had documented spontaneous HBe-seroconversion by serology, who 
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had stored serum at suitable timepoints for analysis. None of them received interferon or 
nucleoside analogue therapy before seroconversion. 
 
Sample selection: 
1. Baseline: serum collected more than 6 months before HBe-seroconversion; 
2. Pre-seroconversion: serum collected within 6 months before or on the day of HBe-
seroconversion; and 
3. Post-seroconversion: serum collected after, but within one year of HBe-
seroconversion.  
 
These samples correspond to 1) early immune clearance phase; 2) late immune clearance 
phase; and 3) immune control phase/ inactive carrier state, in the natural history of chronic 
HBV infection (Figure 1.6). 
 
For control, we identified 9 patients who were in immunotolerant phase, and had serum 
collect over a similar 2-year period, during which the HBeAg remained positive, the HBV 
DNA remained stable and high (>107 copies/ml), and had normal ALT. 
 
The serum DNA and qPCR analysis were carried out using the same methods as above.  
 
 
3.2.5.2  Results 
 
The total DNA was extracted from sera, and the total and splice HBV DNA analysed using 
quantitative PCR as presented before. 
! 84!
 
The serum HBV DNA of the 13 patients with spontaneous HBe-seroconversion fell from 
1.35 x 106 copies/ml at baseline to 2.05 x 104 copies/ml just before HBe-seroconversion.  It 
remain at approximately the same level in the first year post-SC (figure 3.11). 
 
 
Figure 3.11 Changes in the mean total HBV DNA at 1) Baseline, 2) Pre-HBe 
seroconversion (Pre-SC) and 3) Post-HBe seroconversion (Post-SC).  The total HBV 
DNA was derived from the qPCR assay readings based on primer sets C-140 and P-188, 
which were not affected by splicing (Figure 3.3). 
 
The proportion of HBV splice variants in the patients who underwent spontaneous HBe-SC 
rose from a median of 16% at baseline, to 48.7% just before HBe-SC (Wilcoxon Signed 
Ranks Test (WSRT): p = 0.011), then fell to 33.4% after seroconversion (WSRT: p = 0.055) 




Figure 3.12  Box plot showing the changes in the percentage of splice/total HBV DNA 
at Baseline, Pre-SC and Post-SC. Statistical analysis between each group was performed 
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Figure 3.13  Changes in the mean total HBV DNA of 9 immunolerant HBV patients at 
1) Baseline (TP1), and a 2) second timepoint (TP2) at 2-years from TP1.  The total HBV 
DNA was derived from the qPCR assay readings based on primer sets C-140 and P-188, 
which were not affected by splicing (Figure 3.3). 
 
 
Figure 3.14 Dot blot showing the changes in the percentage of splice/total HBV DNA 






















each point was reflected next to it, and the lines showed the transition of the individuals’ 
percentage of HBV splice/total DNA from TP 1 to TP2.  
 
For the immunotolerant control group, the same measurement for HBV splice variants 
showed a very different picture. Seven of these nine patients had no detectable spliced DNA, 
with 2 outliers. 2 years later, both the outliers became undetectable, but another 2 then had 
detectable spliced variants (figures 3.13 and 3.14).  
 
This was a small patient cohort, but it did suggest that at immunotolerant phase, the 
percentage of HBV splice variants was generally low, even though individuals do fluctuate 
over time. Not surprising, there  were no statistically significant change between the 
proportions of splice variant between TP1 and TP2 (p = 0.808) (figure 3.14). 
 
 
3.2.5.3 Validation of the changes in the proportions of HBV splice variants 
before HBe-seroconversion 
 
We identified a separate cohort of 25 chronic HBV patients with stored serum in the immune 
clearance phase. All these patients had documented spontaneous HBe-seroconversion by 
serology, who had stored serum at suitable time points for analysis.  
 
Sample selection: 
1. Baseline: serum collected more than 6 months before HBe-seroconversion; 





Figure 3.15 Box plot showing the changes in the percentage of splice/total HBV DNA 
at Baseline and Pre-SC.  
 
Amongst the validation set of spontaneous HBe-seroconversion patient samples, the 
proportion of HBV splice variants in the patients who underwent spontaneous HBe-SC rose 
from a median of 61% at baseline, to 75% just before HBe-SC (Wilcoxon Signed Ranks Test 
(WSRT): p < 0.001) (figure 3.15). 
 
Compared to the first spontaneous seroconversion cohort, the percentage of SP/total in the 
validation cohort was higher (likely due to random differences between different cohorts), but 
the rising trend from early to late immune clearance phase was the same (Figure 3.12 and 
3.15). The values were also higher than the mean levels of the HBV patients during 




3.2.6  Identifying the mechanism for the relative rise in HBV splice variant 
during immune clearance phase of HBV infection 
 
The reason for the relative rise in HBV splice variant during immune clearance phase was 
unclear. Furthermore it completely contradicted with the postulation that the HBV RNA 
splicing contributed to immunotolerance through immunomodulatory role by producing the 
HBV splice-generated protein (HBSP) or the production of defective viral particles.  
 
 
3.2.6.1  The potential mechanisms 
 
The increased proportions of HBV splice variants occurs in the background of falling total 
HBV DNA during immune clearance phase. The process of HBV pgRNA splicing leading to 
defective viral particle and HBSP production was discussed in section 1.3.1, . We 
hypothesize that there are two potential mechanisms causing a relative rise in spliced 
RNA/DNA production (Figure 3.16).  
 
1. A decreased full-length pregenomic RNA export resulting in a relative fall in the 
production of wild-type viral particles. 
- We postulate that there may be mutations that accumulate at the PRE region (section 
1.3.2.2) during clonal selection during the immune clearance phase. This may then 
cause a decrease in the efficiency of the PRE to export the unspliced HBV pgRNA 
from the nucleus to the cytoplasm, which will then cause a decrease in the genome-
length HBV DNA production. The spliced RNA can be exported by the splicing-
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dependent mRNA export mechanisms discussed earlier, and hence not affected by 
PRE function. 
 
2. Partial inhibition of the viral polymerase (reverse transcriptase) leading to a relative 
decrease in the reverse transcription of the longer wild-type HBV pgRNA, compared 
with the spliced RNA.  
- It had been demonstrated that cytokine-mediated control of virus replication related 
to HBV-specific T cell responses were linked to immune clearance (Guidotti and 
Chisari 2001).  Of all the cytokines, interferon-(IFN-) was probably the most 
established cytokine shown to strongly inhibit HBV replication (Bertoletti and 
Gehring 2006). We postulate that, during immune clearance phase, the cytokines, 
especially the interferons, suppressed the HBV polymerase and affects the production 
of the 3.2 kb wild-type HBV genome greater than the (1.2 kb shorter) spliced genome, 





Figure 3.16  Production of wild-type HBV, spliced HBV RNA and its products, in 
relation to the potential mechanisms (interruption of pathway marked by blue star 
symbol) of relative increase in the production of HBV splice variants. 
 
 
3.2.6.2  Polymorphism of the HBV RNA export element in high and low 
HBV splice variant producers 
 
To test out the first hypothesis, we carried out cloning and sequencing of the HBV PRE 
region (figure 3.17) of the patients’ DNA samples from section 3.2.1, where we had earlier 
measure the percentage of HBV splice variants. The patients are divided into high splice 
variant (upper 50th percentile, >22%) and low splice variant  (lower 50th percentile, <22%) 




Figure 3.17 The location of the post-transcriptional regulatory element (PRE) on the 




Phylogenetic analysis of sequences: The post-transcriptional regulatory element (nt. 1217–
1582) were aligned using Clustal X version 1.810 and edited manually using BioEdit version 
5.07 (Tom Hall, Department of Microbiology, North Carolina State University). The 
dominant clone for each patient was selected by manual inspection of the phylogenetic tree, 
and compared with the dominant clones from the other patients (Figure 3.18). We specifically 





Figure 3.18 Phylogenetic tree of the HBV PRE sequence alignment, analysed by MEG 






Figure 3.19 The alignment of the dominant PRE sequences from chronic HBV 
patients, showing mainly genotype (B & C) specific differences.  There was no specific 











Results:  There were no consistent point mutation found that was associated with higher or 
lower levels of HBV splice variants in the PRE region. Amongst the patients’ HBV clones 
studied, they can be divided into 2 groups, characterised by genotype (B and C)-specific 
differences (figure 3.19). 
 
Conclusion:  There was no evidence that PRE mutation and hence its function, were 
associated with the levels of HBV splice variants in the serum DNA extracted from chronic 
HBV patients in our cohort. Thus hypothesis (1) cannot explain the increase in the splice 
variant proportion during the immune clearance phase as observed earlier. 
 
 
3.2.6.3  HBV polymerase inhibition by lamivudine treatment increased the 
proportion of HBV splice variants 
 
To test the second hypothesis that inhibition of the viral polymerase (reverse transcriptase) 
leading to a relative decrease in the reverse transcription of the longer wild-type HBV 
pgRNA compared with the spliced RNA, we looked for the effect of a direct HBV polymerse 
inhibitor, lamivudine, on the proportion of splice variants. 
 
We identified a group of 15 patients treated with lamivudine in two earlier clinical trials, who 
had serum stored at suitable time points. The patients were all HBeAg positive at baseline, 
and treated with lamivudine monotherapy. Serum samples were collected every 3 months and 
stored at -70 degree Celcius immediately. Total DNA was extracted from 200 uL of each 
serum sample using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) as described 
earlier, analysed for the HBV wild-type and splice variant DNA by qPCR assay.  
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The patients were further divided into 2 groups based on their subsequent HBe-
seroconversion status. Group 1 (n = 8) consist of patients who developed HBeSC during the 
cause of their lamuvidine therapy, and Group 2 (n =  7) were patients who remain HBeAg 
positive through the entire duration of their antiviral therapy. 
 
Sample selection: 
1. Baseline: serum collected at baseline, before the commencement of lamivudine 
treatment; 
2. Time point 1: serum collected at 3 months of lamuvidine treatment, and before HBe-
seroconversion; and 
3. Time point 2: serum collected after HBe-seroconversion (Group 1); or the last serum 
collected while on lamivudine trial  (at the end of 3 years) (Group 2). 
 
The effects of HBV polymerase inhibition on the total HBV DNA by lamivudine, and the 
effects of HBeSC on the proportions of spliced/total HBV DNA were shown in Figure 3.20 




Figure 3.20       Change in total HBV DNA after lamivudine treatment at the 3 time 
points, divided into HBe-seroconverters and non-seroconverters. Amongst the non-
seroconverters, a few patients developed lamivudine-resistance towards the later phase of the 








Figure 3.21  Box plot showing the changes in the percentage of splice/total HBV DNA 
at Baseline, Time point 1 and Time point 2, of the seroconverters and non-
seroconverters who received lamivudine therapy. The median percentage for each time 
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p = 0.224 
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For the lamivudine treated group, both HBe-SC (Group 1) and non-seroconverters (Group 2) 
had an increase in the proportions of splice variants after 3 months of treatment 
(seroconverter, median = 13.8% to 83.8%, WSRT: p = 0.025; non-seroconverter, median = 
1.25% to 64.8%, WSRT: p = 0.012). After HBe-SC, there was a significant fall of splice 
variant proportion, but not the non-seroconverters right till the end of lamivudine treatment 
(WSRT: seroconverter, p = 0.050; non-seroconverter, p = 0.237).  
 
The pattern of change, particularly for group 1, mirrors that of the spontaneous HBe-
seroconverters in Figure 3.12. This provided support for hypothesis (2), i.e. inhibition of the 
HBV polymerase cause a relative increase in the proportion of the HBV splice variants. 
 
To validated the effect of lamivudine treatment, we tested a separate lamivudine-treated 
cohort of 20 HBV patients. All these patients received lamivudine 100 mg daily for clinical 
indication of chronic active hepatitis, and had provided consent for the storage of the leftover 
serum for research purpose.  
 
Sample selection: 
1. Baseline: serum collected at baseline, before the commencement of lamivudine 
treatment; 




Figure 3.22  Box plot showing the changes in the percentage of splice/total HBV DNA 













In the validation cohort, we demonstrated an increase in the proportions of splice variants 
after lamivudine treatment (median = 66.2% to 79.3%, WSRT: p = 0.008) (figure 3.22), 
which was consistent with the rise between baseline and time point 1 in Figure 3.21. 
 
 
3.2.6.4  Interferon-alpha therapy increased the HBV splice variant DNA 
levels 
 
We had so far demonstrated that lamivudine, a nucleoside analogue that specifically inhibits 
HBV polymerase, was associated with a relative increase in HBV splice variant level. In 
immune clearance phase, this inhibition was likely a direct or indirect result of viral 
suppression by one or more of the cytokines, particularly interferon-γ, which had been 
established to have potent antiviral effects (Guidotti and Chisari 2001).  
 
Interferon-alpha was one of the approved treatment options for chronic hepatitis B infection. 
Our lab had conducted a study earlier to examine the effects of interferon therapy on the 
evolution of HBV quasispecies (Lim, Cheng et al. 2007). Using the left over DNA specimens 
extracted with the same method, we evaluated the effects of IFN-α on the HBV splice variant 
production. 11 patients with sufficient DNA samples were available for the qPCR analysis for 
splice variant level. 
 
The patients selected received IFN-α did so as part of a clinical trial of lymphoblastoid IFN 
(Wellferon; GlaxoWellcome, Beckenham, United Kingdom) and received between 3 and 5 
million international units 3 times weekly for 24 weeks. 5 patients were IFN-responders 
(achieved HBe-seroconversion) and the other 6 patients were non-responders. The mean 
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Figure 3.23 Box plot showing the changes in the percentage of splice/total HBV DNA 









There was an increase in the proportions of splice variants after interferon-alpha treatment 
(median = 74% to 94%, p = 0.009) between the baseline and the post-IFN time points (Figure 
3.23). This again was similar to the changes in splice variant ratio during spontaneous HBe-
seroconversion and with lamivudine therapy (a direct polymerase inhibitor), which supports 
the hypothesis that the mechanism for the relative rise in the splice variant may be linked to 
HBV polymerase inhibition. The interferon pathway, which are strongly activated during the 
immune clearance phase in spontaneous seroconverters, may also be implicated.  
 
 
3.2.7  HBV splice variant levels and the development of liver cirrhosis 
 
Marschenz et al. (Marschenz, Endres et al. 2006) characterized the phenotype of these 
complex HBV variants from a highly viremic long-term immunosuppressed renal transplant 
recipient with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who developed end-
stage liver disease. The authors concluded that the development of cirrhosis was associated 
with the accumulation of complex variants, which showed considerably reduced levels of the 
major spliced pregenomic RNA, an increased level of pregenomic RNA, and a partial or 
complete defect in hepatitis B e antigen, core, and surface protein expression/secretion. 
 
As this study only involved the study of one patient, in order to determine if the this reduction 
in the spliced RNA and the production in the defective viral particles was generalizable, we 
looked a number of chronic HBV infected patients who were developing liver cirrhosis and 




We identified a retrospective cohort consisting of 7 chronic HBV patients with histological 
confirmation of liver cirrhosis (Cirrhosis group), and another 8 HBV patients with no clinical 
or radiological evidence of liver cirrhosis as control (Non-cirrhosis group). For each patient 
in both groups, they must have stored serum specimen collected on the day of liver biopsy 
(Cirrhosis group), or on the day of US/CT scan showing absence of cirrhosis (Time point 2). 
Time point 1 was the serum collected 1 year before time point 2 to serve as baseline. 
 














Figure 3.24 Bar chart depicting the changes in the percentage of splice/total HBV 
DNA at 1) Time point 1 (at baseline, blue bar), and 2) Time point 2 (at the time 
confirmation of liver cirrhosis/no cirrhosis, purple bar) for each individual.  
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Results: In the group that progressed to liver cirrhosis (n = 7), 4 patients had decrease in the 
%SP and the other 3 were either increase or no change (Figure 3.24). The median %SP was 
13.5% before cirrhosis, and 3.4% at the time of diagnosis of liver cirrhosis (p = 0.35). In the 
non-cirrhosis control (n = 8), the median %SP was 0% (Time point 1) and 20.2% (Time point 
2), 1 year apart (p = 0.6). 
 
Conclusion: There was no significant fall in the proportion of splice variants as the small 
patient cohort progressed to the diagnosis of liver cirrhosis, as suggested by earlier study. 




3.3  Discussion 
 
The work in this chapter confirms previous findings that HBV splice variants are common 
and often more abundant than the full-length HBV genome (Terre, Petit et al. 1991, 
Rosmorduc, Petit et al. 1995, Gunther, Sommer et al. 1997), and further demonstrate that it 
fluctuates over time in the same patient as he/she transits through different phases of the 
natural history of HBV infection. Through the new real-time PCR assay system to quantify 
the HBV splice variants, we are the first to established that this measurement through serum 
correlated significantly with the liver tissue HBV measurement. We found that during the 
immunotolerant phase, the splice variant levels were low compare with the wild-type, but this 
increased significantly during immune clearance, peaking just before HBe-seroconversion. 
We ruled out that mutations at the PRE region contributed to this fluctuation, and provided 
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some evidence that this was likely to be due to interferon/other cytokine inhibition of the 
HBV polymerase during immune clearance. 
 
 
3.3.1  HBV DNA – What are we actually measuring? 
 
HBV DNA is one of the important markers of viral replication, and had been well-validated 
to correlate with hepatitis B disease progression (Chen, Yang et al. 2009), as well as 
treatment response (Liaw 2002). Both case-control and cohort studies have shown a 
significant association between serum HBV DNA levels and the risk of liver cirrhosis and 
hepatocellular carcinoma. These studies also shown that reduction in HBV DNA levels 
correlate strongly with improvements in liver histology. 
 
However earlier studies (Abraham, Lewellyn et al. 2008) and our own data demonstrated that 
a variable and often very high proportion of the total HBV DNA measured (sometimes 
greater than 90%) actually consist of HBV splice variants which were defective – without the 
complete coding sequences for the HBV surface and polymerase gene, and hence unable to 
complete the entire viral life cycle. Traditionally more commercial HBV DNA real-time PCR 
assays (e.g. the COBAS Amplicor HBV Monitor test) and published qPCR assays (Loeb, 
Jerome et al. 2000) have targeted the X- or pre-core sequences, which were noted to be 
highly conserved.  
 
However our data suggests that under circumstances such as during the immune clearance 
phase, or during treatment with lamivudine or interferon-alpha, the number of viable, 
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genome-length HBV particles may be over-estimated if the real-time PCR assays target the 
sequences common to both spliced and unspliced form of HBV DNA. 
 
 
3.3.2  A new marker for predicting  HBe-seroconversion 
 
In the liver specialist clinic, HBV patients often present for the first time in the immune 
clearance phase, when there is active liver inflammation with consequent abnormal liver 
function tests. Their HBeAg are usually positive at the time of presentation, and it is possible 
that some of them will develop spontaneous HBe-seroconversion, and enter the inactive 
phase. For others, the liver inflammation may be protracted and some may take years before 
successful seroconversion, with the development of serious liver injury. These patients 
should be treated with antiviral agent early. However at initial presentation, it is often 
difficult to tell which patient will develop spontaneous HBeSC early, or would go into a 
protracted course. 
 
Our data suggest that the proportions of splice variants rise in patients at immune clearance 
phase, peak just before HBeSC, and then fall right after seroconversion. The trend is 
consistent for our validation samples. It may be promising as a potential prognotic factor for 
spontaneous HBe-seroconversion, which may prevent unnecessary treatment. Due to the 
small sample size and limited time points, it is still prematured to determine the threshold or 
gradient of rise for making a prediction. A larger, prospective cohort of HBV patients in 




Another interesting proposition is to explore the potential of the change in splice/total ratio to 
predict response to IFN-alpha treatment. However due to the very small number (n= 11), and 
about half of the recruited patients were non-responders (n = 6), the number of IFN-responder 
is not sufficient to draw a conclusion. 
 
 
3.3.3  What is inhibiting the HBV polymerase during immunoactive phase? 
 
Our knowledge about immune control of HBV had expanded in the last 20 years of research, 
but much remained unclear. We now know that HBV control occurs when the CD8+ T cells, 
along with other components of innate and adaptive immunity, were activated, which triggers 
a broad-based cascade that amplifies the HBV-specific responses, at least in HBV-transgenic 
mice and the cell culture systems (Bertoletti and Gehring 2006). Many cellular genes were 
known to be induced during the immune clearance of HBV, including T cell  genes (CD3, 
CD 53, Granzyme A, IL 10-R, Leupaxin, TcR-beta & gamma), IFN-gamma induced genes 
(GBP1 & 2, LMP-2, Mec11, MHC class I  & II, MIG, MIP-1beta, PA28alpha, RANTES, 
Ubiquitin D), and other miscellaneous genes (adenylate cyclase, C1q, CD48, IgG Fc receptor, 
tyrosine kinase binding protein, uncoupling protein 2) (Wieland and Chisari 2005). None of 
these had been studied in the context of HBV RNA splicing  or its products.  
 
Our data, based on the study of the pattern of change in the HBV splice variant levels in 
different patient cohorts, points to a IFN-induced anti-HBV polymerase activity being 
activated during the immune clearance phase. With such a wide myriad of potential candidate 
genes, to develop a suitable in vitro model to investigate this will not be easy, and is probably 
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3.3.4  HBV splice variant: is it just a effect of HBV polymerase function, or 
does it have more specific roles in the pathogenesis of HBV infection? 
 
Our work in this chapter focused on following individual patients over multiple time points to 
identify possible possible reasons for the changes in the abundance of HBV splice variant 
DNA over the course of the disease. It turns out the the evidence suggest the fluctuation 
occur during immune clearance, which in turn was likely related to HBV polymerase 
inhibition by certain immune mechanism, likely the interferons which had been established as 
a key component to the immune clearance of HBV in cell and animal models. 
 
In a way, this seems to imply that HBV splice DNA is but a passive reflection on the function 
of the HBV polymerase, a byproduct of suppressed reverse transcription function, and by 
itself is unimportant to disease progression. Preiss et al (Preiss, Littlejohn et al. 2008) 
examined a group of 192 HBV-monoinfected patient samples of genotypes (A-D) and 
differing severity of liver disease cross-sectionally (single time point) using a different qPCR 
assay that can detect singly spliced DNA. Spliced DNA was detected in 90% of the patients, 
and there was no association with the ALT, HBeAg status, HBV DNA levels, fibrosis levels, 
liver cirrhosis, genotype or drug treatment. However the authors found that the lamivudine 
resistant mutation of the HBV polymerase gene altered the balance between the spliced and 
genomic length DNA. Lamivudine resistance is caused by the HBV polymerase gene 
mutation at the rtM204 position. This mutation, although preferentially selected by 
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lamivudine therapy, decreases the polymerase gene function and viral replication fitness 
significantly compared with the wild type virus. The authors’ conclusion was that the relative 
abundance of HBV splice variant DNA was largely dependent on the integrity and function 
of the HBV polymerase. 
 
In a way our observation from different angles of the HBV splice DNA levels brought us to 
the same conclusion. This however, does not address our initial goal of explaining why HBV 
RNA splicing mechanism was so well-conserved and its physiological role(s). This will be 

















Chapter 4: HBV spliced RNA supports viral replication by 
functioning as dedicated HBV core mRNA. 
 
4.1  Introduction 
 
4.1.1  Background and Hypothesis 
 
HBV splice variant was reported to be associated with the chronic course of HBV infection 
and viral multiplication in vivo (Rosmorduc, Petit et al. 1995). Another argument for the 
possible biological importance of splicing in HBV is the conservation of eight of the nine 
known functional splice donor and acceptor sites in all known HBV genotypes (Gunther, 
Sommer et al. 1997).  
 
However, the analysis of viral genomes with mutations in two frequently used splice sites 
revealed no effect on viral replication in transfected hepatoma cell lines (Su, Lai et al. 1989). 
Although splicing of the the HBV pgRNA appears not to be essential for tranfected HBV 
model, other aspects of the viral life cycle may still be affected in vivo. In fact, a spliced 
mRNA of the HBV-related duck hepatitis B virus (DHBV) has been shown to be functionally 
important for virus replication in infected primary duck hepatocytes and ducks, but not for 
virus formation in cells transfected with viral genomes (Obert, Zachmann-Brand et al. 1996). 
However unlike human HBV, none of these mRNAs are encapsidated and reverse transcribed 
due to the deletion of the encapsidation signals on the pgRNA by these splicing events. 
Therefore, the biological role of HBV RNA splicing (if any) is likely to be different from 
DHBV, and requires further work. 
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Despite losing most of the coding sequences for surface and polymerase ORF, the spliced 
RNA retains the promoters and coding regions of the core and X proteins (see figure 4.1). 
Functionally, this was demonstrated by the transfection of the spliced HBV DNA alone into 
the Huh7 cell lines (Rosmorduc, Petit et al. 1995), leading to a marked intracellular 
accumulation of the major core protein (HBcAg) and to an increased secretion of hepatitis B 
e antigen (HBeAg). The X mRNA was also increased, though there was no obvious increase 
in X protein on the Western blot. In 2003, Soussan et al. (Soussan 2003) discovered that it 
also expressed a novel hepatitis B splice generated protein (HBSP), whose role is still not 













Figure 4.1 The ORFs of HBV spliced RNA. The spliced RNA retains the coding regions 
for Pre-core/Core and X peptide, and forms a new coding regions for HBSP. 
 
Whilst it is clear that the HBV pgRNA splicing is not absolutely necessary to complete the 
viral life cycle, we hypothesize that the spliced RNA can function as dedicated mRNA for 
more efficient native viral proteins production (Core or X peptide), compared with the 













4.1.2 Co-transfection of HBV and expression constructs into hepatoma cell 
lines 
 
4.1.2.1  The generation of splice acceptor deficient HBV genome  
 
In order to study the effect of varying levels of spliced HBV RNA on the replication of full-
length HBV, we needed to carry out site-directed mutagenesis to ensure that this full-length 
viral genome cannot undergo further splicing, so that the amount spliced RNA was entirely 
controlled by the quantity of co-tranfected spliced HBV DNA. 
 
A site-directed mutagenesis of nt. G488!C substitution was carried out based on previous 
report (Su, Lai et al. 1989) to inactivate the common splice acceptor site (figure 4.2). The 
mutation was carried out on a previously cloned (Topo XL, Invitrogen, Carlsbad, USA) 
genotype C, full-length HBV (233K4) from a patient with HBV-associated hepatocellular 
carcinoma, using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Heidelberg, 
Germany) according to the manufacturer’s instruction.  
 
In brief, the 233K4 containing TopoXL plasmid was denatured and FPLC-purified 35 bp 
primer (Sigma-Aldrich, Singapore) containing the G488C substitution was annealed. Using 
the nonstrand-displacing action of PfuTurbo DNA polymerase, the mutagenic primer was 
extended and incorporated in the nicked circular strands. The cycling condition was 95°C for 
30 seconds, 55°C for 1 minute, and 68°C for 6 min. The methylated, nonmutated parental 
DNA templated was then digested with DpnI. The circular, nicked dsDNA containing the 
mutation was transformed into competant E. coli cells which repaired the nicks in the 
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mutated plasmid. The plasmid DNA was extracted and sequenced to confirm that the correct 




Figure 4.2 A. The site of point mutagenesis intended to eliminate the splice acceptor 
site common to the patient sample studied. B. The final sequence alignment of the 
original (233K4) and mutated (233K4mut8) HBV-containing plasmid, demonstrating 




We also cloned a 2 kb singly-spliced HBV DNA using the same vector from the same 
patient’s serum-extracted DNA (K4SP). The sequences were identical excepted for the 
spliced region which deleted the sequence between nt 2447 and nt 489 (splice variant type 1), 
which was the most common form report and in our earlier samples. 
 
When the full-length HBV DNA, K4 (with splice acceptor deleted) and the K4SP were 
transfected into a hepatoma cell line (Huh7), both the full-length and spliced HBV RNA were 









Figure 4.3  Reverse transcription-PCR of the total RNA from Huh 7 cells transfected 
with K4 and K4SP. Diagram (a) showed the map of the full-length HBV genome K4 and the 
corresponding spliced RNA K4SP. The positions of the primers SP1 and SP2 (Table 2.1) 
(Sheen, Tsou et al. 2007) which were used for the RT-PCR were labeled. The control was 
RT-PCR product of Huh7 cells transfected with K4 only, lanes 1-3 were the RT-PCR results 
of 3 different samples transfected with both K4 and K4SP DNA at 1:1 ratio. The RT-PCR 







4.1.2.2  The choice of cell line for transfection experiment 
 
In general, there are two forms of cell models for the study of HBV pathogenesis. Most 
studies untilised hepatoma cells (e.g. HepG2 and Huh7) that can be transiently transfected 
with HBV genome and carried out viral replication lasting a few days. The other popular 
model is a stably integrated HBV expression model (HepG2.2.15 cell line) (Sells, Chen et al. 
1987) that contains two head-to-tail dimers of  1.3x genotype A HBV genome organized in a 
HBV in a tail-to-tail orientation. It has the advantage of being able to produce the genome-
length HBV DNA constantly, and without the need to quantify the transfection efficiency, but 
lacks the possibility of introducing mutations to the HBV genome to study the effects of 
specific mutation-of-interest. 
 
We extracted the total DNA from the cells and medium of HepG2.2.15 cells using the 
QIAmp blood mini kit serum and tissue protocol (Qiagen, , Hilden, Germany) as described 
above. To measure the type and amount of HBV splice variants that it produced, we 
performed a RT-PCR  using SP1 and SP2 primers (Sheen, Tsou et al. 2007) as described 
above. Interestingly, there was no spliced DNA product that can be detected in both the cell 




Figure 4.4  Electrophoresis of the RT-PCR product of HepG2.2.15 cell- and medium-
extracted DNA using SP1 and SP2 primers which flanks the intron region of the HBV. 
Only unspliced DNA amplicon (1584 bp) was detected, and none of the smaller (350 bp) 
spliced DNA amplicon was formed, despite repeated experiments. 
 
Based on the limited information provided in the Sells et al. 1987, the vector contained two 
head-to-tail dimers of HBV in a tail-to-tail orientation. We speculate that it is due to the 
organization of the initial HBV construct that was integrated into the HepG2.2.15 cell 
genome that disrupted the splice site organization. Our PCR result (data not included in the 
thesis) actually showed 1.3x HBV genome in each of the dimer unit. The exact mechanism 
remained to be proven. 
 
It became clear that each of the cell model can serve different purpose in different 
experiments. For the study of effects of spliced RNA and the effects of individual viral 
proteins on HBV replication, the integrated, stably expressing Hep2.2.15 cells was the better 
model, as it provided a stable wild-type HBV DNA expression and no spliced variant of its 
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own. To study the effects of specific mutations and targeted inhibition of the splicing 
mechanism (e.g. RNA interfeerence), the transiently transfected hepatoma cell lines provided 
more possibilites of controlling the genotype and the quantity of DNA transfected into these 
cells. For the transient transfection experiments, we chose the Huh7 cells for most of 
experiments as we had more experience with its handling and for its ease of maintenance. 
 
 
4.1.2.3  The construction of HBV core and X expression vector and 
determination of the most efficient transfection reagent for each cell types 
 
The core (nt. 1901 - 2458) and X (nt. 1274 – 1838) coding region of a genotype C HBV 
genome from a chronic HBV patient was inserted into the pcDNA3 expression vector 
(Invitrogen, Carlsbad, USA), and positive clones were confirmed by Sanger sequencing.  
 
We carried out a series of transfection experiments using the HBV core and X expression 
plasmids to determine the best transfection method to achieve the greatest efficiency. The 
chemical transfection reagents we tested include the Effectene trasnfection reagent (Qiagen, 
Hilden, Germany), Lipofectamine (Invitrogen, Carlsbad, USA), XtremeGene 9 and Xtreme 
GENE HP (Roche Applied Science, Singapore).  
 
In brief, 2 x 105 Huh7 or HepG2.2.15 cells were seeded into each well of a 12-well plate and 
allowed to recover for 24 hours, day before the transfection. For comparison, 2 ug of the 
pcDNA3-core expression plasmid was complexed with each of the above-mentioned 
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transfection reagent according to the manufacturers’ instruction, and the DNA-transfection 
reagent complex was added into each well, gently swirl to ensure even distribution.  
 
After 24 hours, the medium containing the transfection reagent was changed with fresh 
medium and a further 48 hours later, the cellular proteins were extracted, followed by SDS-
PAGE and Western blot described in Sections 2.5 to 2.7. The following primary and 
secondary antibodies, together with their concentrations, were used for the immunoblotting of 
the core and X proteins. 
 
Primary antibodies 
1. HBV core protein: Lifespan Bioscience (LSBio) rabbit anti-HBcAg polyclonal antibody 
(Cat no: LS-C67451); Stock concentration: 1mg/ml; Dilution factor: 10,000X in blocking 
buffer. 
2. HBV X protein: Santa Cruz Biotechnology mouse anti HepBxAg (6D456) sc-71239 
monoclonal; Stock concentration: 0.2mg/ml; Dilution factor: 500X in blocking buffer 
 
Secondary antibodies 
1. Pierce ImmunoPure® goat anti-mouse HRP (Prod # 31430) 
2. Pierce ImmunoPure® goat anti-rabbit HRP (Prod # 31460) 




Figure 4.5 Comparing the HBV core expression in HepG2.2.15 cells transfected with 
2 ug pcDNA3-core expression plasmid using different transfection reagents. Lane 1: No 
transfection (Baseline level of stable expression); Lane 2: Effectene; Lane 3: XtremeGENE 9; 









Figure 4.6 Comparing the HBV core expression in Huh7 cells transfected with 
pcDNA expression plasmids using different Effectene and XtremeGENE HP reagents. 
(Left) Lane 1: No transfection; Lane 2: 1µg pcDNA3 (no insert) using Effectene; and Lane 3: 
1µg pcDNA3-core using Effectene; Lane 4: 1µg pcDNA6-core (alternate contruct) using 
Effectene. (Right) Lane1: No transfection; Lane 2: 1µg pcDNA3 (no insert) using 
XtremeGENE HP; Lane 3: 1µg pcDNA3-core using XtremeGENE HP; and Lane 4: 1µg 





Figure 4.7  Comparing the HBV X protein expression in Huh7 cells transfected with 
pcDNA expression plasmids using the Effectene reagent. Lane 1: Positive control; Lane 2: 




Figure 4.8  Comparing the HBV X protein expression in HepG2.2.15 cells transfected 
with pcDNA expression plasmids using the XtremeGENE HP reagent. Lane 1: Positive 
control; Lane 2: No transfection; Lane 3: 1µg pcDNA3 (no insert); and Lane 4: 1µg 
pcDNA3-HBx.  
 
To summaries, the XtremeGENE HP transfection reagent produce the highest transfection 
efficiency as demonstrated by the core and X protein expression level on Western blot for 
both the Huh7 and HepG2.2.15 cells (figures 4.5, 4.6 and 4.8). Effectene reagent works well 
for Huh7 but very poorly for HepG2.2.15 cells (figures 4.5, 4.6 and 4.7). The Lipofectamine 
and XtremeGENE 9 reagents were inferior for both cell lines (figure 4.5). 
 
These transfection reagents were compared with transfection by electroporation and showed 
that the protein expression were higher with chemical transfection in general for the 
hepatoma cell lines, with fewer cell loss. 
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4.2  Results 
 
4.2.1  The co-transfection of HBV spliced genome enhanced replication of 
full-length HBV DNA 
 
The linear HBV monomers, K4 and K4SP, were released from the vector by SapI digestion 
(New England Biolab, Singapore) and transfected by Effectene Transfection Reagent 
(Qiagen, Hilden, Germany) into the hepatoma cell line Huh7 (passage into 6-well plates 24 
hours earlier, 2 X 105 cells per well) according to the protocol of the supplier. Briefly, the 
DNA was condensed by interaction with the Enhancer in a defined buffer system to form the 
Effectene–DNA complex. Effectene reagent was then added to the condensed DNA in a ratio 
of 1: 25 to produce a condensed Effectene–DNA complexes, which spontaneously formed 
micelle structures. The Effectene–DNA complexes were mixed with medium and directly 
added to the cells. Different ratios of the two plasmid DNAs were used (Table 4.9A) and the 
total amount of DNA used for each transfection was adjusted with vector pGEM-t DNA 
digested by restriction enzymes ApaI and BamHI (New England Biolab, Singapore) to make 
the total amount of DNA used for each transfection identical (0.4ug DNA). The medium 
containing the Effectene-DNA complexes were removed and changed into fresh DMEM 
medium after 24 hours. The cells were harvested 48 hours later (72 hours after transfection). 
Digested vector pGEM-t DNA was used as the mock transfection control. 
 
As reported previously (Sommer, van Bommel et al. 2000), intracellular core particles were 
collected, purified by centrifugation, digested with DNase I (to remove the HBV cccDNA 
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and other replicative intermediate DNA) and the intracytoplasmic HBV DNA were extracted. 
The replication efficiencies of full-length HBV genome were examined by real-time PCR 
using the S-114 primer set as described in section 3.1.2, which detects only wild-type 
(unspliced) HBV DNA. The number of HBV DNA copies in samples was calculated 
according to a standard curve generated from HBV DNA derived from a genotype C full-
length HBV genome cloned into an E. coli plasmid, extracted and serially diluted to the 













A. Experimental setup: The quantity of co-transfected of K4, K4SP and Control DNA 




B. Core-associated HBV DNA (unspliced) extracted from Huh7 cells against the 
quantity of co-transfected K4SP DNA. 
 
C. Excreted HBV DNA (unspliced) extracted from 200 ul of cell culture medium against 















































Figure 4.9 Dose-dependent replication enhancing effect of the 2 kb spliced variant 
K4SP on the full-length HBV DNA.  A) Table showing the ratio of co-transfected K4, 
K4SP and Control DNA.  B) Core-associated, intracytoplasmic unspliced K4 DNA; and  
C) Excreted, unspliced K4 DNA,  against the quantity of co-transfection of K4SP.  
 
The range of molar ratio of K4:K4SP was 1:0 to 1:1. When K4:K4SP was at 1:1 ratio, the   
quantity of the full-length K4 at 72 hours after transfection was approximately 3-fold higher 
compared with K4 with control DNA alone, for both intracytoplasmic as well as excreted 
viral particles (figures 4.9 B and 4.9 C). The increase was dose-dependent and almost linear. 
 
 
4.2.2 The enrichment of HBV core peptide through the transfection of 
core-expressing plasmid enhanced the production of the wild type virus, 
but not by increasing the X peptide. 
 
4.2.2.1  Methods 
 
To test the hypothesis that the addition of either core or the X peptide by the HBV spliced 
RNA helped to enhance the viral replication, we carried out transient transfection of the core 
and X expression plasmids (pcDNA3-core and pcDNA3-X respectively) into the HepG2.2.15 
cell line to determine which is the main rate-limiting factor for HBV production. As shown in 
section 4.1.2.3, the integrated HBV genome in the HepG2.2.15 cell line does not produce 
measurable amount of splice variants. 
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The transfection protocol was identical to that described in Section 4.1.2.3 (table 4.2). In 
brief, 2 x 105 HepG2.2.15 cells were seeded into each well of a 12-well plate 24 hours before 
transfection. 3 ul of the XtremeGENE HP transfection reagent was added to 1ug of plasmid 
DNA (Table 4.2) in 100 ul of DMEM to form a 3:1 transfection:DNA complex, before 
adding into each well. The medium containing the transfection reagent-DNA was removed 24 
hour later and incubated in fresh medium for another 48 hours before being harvested. The 
tests were perform in duplicate, with one well for DNA (as described in Section 4.2.1) and 
the other identical set for RNA extraction (Qiagen RNeasy Mini Kit). The cell culture 
medium was also collected for DNA extraction (using QIAmp DNA Blood Mini Kit as 
described earlier) and HBsAg levels by Monolisa HBsAg Assay (Bio-Rad, Singapore) 
according to the manufacturer’s instruction. 
 
The real-time PCR analysis of the HBV DNA levels after core enrichment was carried out 
using a published HBV Taqman assay (Loeb, Jerome et al. 2000), targeting a conserved 
region in the X gene. The DNA standards were generated from a HBV-cloned plasmid 
(248O3), diluted to the required concentration. The experiments were repeated at least 2 










Transfection setup (for 
DNA) 
Well 
Transfection setup (for 
RNA) 
1 No transfection 7 No transfection 
2 Mock transfection 8 Mock transfection 
3 0.5 µg pcDNA3-core 9 0.5 µg pcDNA3-core 
4 1 µg pcDNA3-core 10 1 µg pcDNA3-core 
5 0.5 µg pcDNA3-HBx 11 0.5 µg pcDNA3-HBx 
6 1 µg pcDNA3-HBx 12 1 µg pcDNA3-HBx 
 















4.2.2.2  Transfection of pcDNA3-core plasmid into HepG2.2.15 cells 
 
A.  Intracellular HBV DNA 
 
B.  Excreted HBV DNA 
 
Figure 4.10 HBV DNA extracted from (A) HepG2.2.15 cells, and (B) 200 ul of culture 
medium,  against the quantity of transfected pcDNA3-core expression plasmid (0 ug, 0.5 
ug, 1 ug respectively) at 72 hours post-transfection.  
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There was significant increase in the production and excretion of HBV DNA by the 
HepG2.2.15 cells with supplementation of core peptide through transient transfection of the 
core-expressing plasmid DNA alone (figure 4.10). Again, there appeared to be a significant 
dose-effect with the  amount of core-expression plasmid being transfected.  
 
The total HBV RNA levels were also analysed. Reverse transcription was performed using 
the First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, USA) using the 
oligo(dT)18 primer. The cDNA was quantified using the same HBV Taqman assay as above, 
and the pgRNA was quantified by published qPCR method (Pollicino, Belloni et al. 2006). 
All the cDNA readings were normalized with the β–actin levels measured by SYBR green 
qPCR using β–actin specific primers listed in Table 2.1. 
 
Figure 4.11 (A) Quantitative RT-PCR of total HBV RNA against the quantity of 
transfected pcDNA3-core expression plasmid (0 ug, 0.5 ug, 1 ug respectively) at 72 
hours post-transfection, normalised with β–actin levels.  (B) Electrophoresis of the RNA 
extracted from HepG2.2.15 cells (from wells no. 7-12 on table 4.2) in 1% TAE gel with 
ethidium bromide staining. Lanes 1 & 2: Mock Tfx, lanes 3 & 4: Tfx 0.5ug core, lanes 5 & 




Figure 4.12 HBV pregenomic RNA levels against the quantity of transfected pcDNA3-
core expression plasmid (0 ug, 0.5 ug, 1 ug respectively) at 72 hours post-transfection, 
normalised with β–actin levels.   
 
The total HBV RNA levels did not change significantly with the increase in core peptides, 
although there appeared to be a positive trend (figure 4.11). However the increase in the HBV 
pgRNA production was very marked (Kruskal-Wallis Test, p=0.023) with 1ug of pcDNA3-
core plasmid transfection (figure 4.12). The yield of the total RNA from all the wells, as 
visualised on gel electrophoresis, were satisfactory. 
 
 
4.2.2.3  Transfection of pcDNA3-X plasmid into HepG2.2.15 cells 
 
From the same experiment in Section 4.2.2.2, separate wells of the HepG2.2.15 cells were 
transfected with X expression plasmids (pcDNA3-X) at 0.5 ug and 1ug to see the effect of X-
enrichment on the viral particle production. The real-time PCR assay for HBV DNA and 
p=0.023!
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cDNA was performed using the primer set S-222 (targeting the S region) with SYBR green 
fluorescence, instead of the  HBV Taqman assay (Loeb, Jerome et al. 2000) which detected a 
part of the X sequence (over-expressed by transfected plasmid). The cDNA were normalized 
with the β–actin levels measured by SYBR green qPCR using β–actin specific primers listed 






















A.  Intracellular HBV DNA 
 
B.  Excreted HBV DNA 
 
Figure 4.13 HBV DNA extracted from (A) HepG2.2.15 cells, and (B) 200 ul of culture 
medium,  against the quantity of transfected pcDNA3-X expression plasmid (0 ug, 0.5 
ug, 1 ug respectively) at 72 hours post-transfection. The control is mock transfection 





Unexpectedly, there was a decrease in the mean intracellular HBV DNA levels with 
enrichment of X protein compared with the control, which just reached statistical significance 
(p=0.050) (figure 4.13). There was no significant difference in the excreted viral particle in 















Figure 4.14 Quantitative RT-PCR of HBV RNA (S-222) against the quantity of 
transfected pcDNA3-X expression plasmid (0 ug, 0.5 ug, 1 ug respectively) at 72 hours 
post-transfection, normalised with β–actin levels.   
 
 
Figure 4.15 HBV pregenomic RNA levels (Pollicino, Belloni et al. 2006) against the 
quantity of transfected pcDNA3-X expression plasmid (0 ug, 0.5 ug, 1 ug respectively) at 
72 hours post-transfection, normalised with β–actin levels.   
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The qPCR assay revealed significantly elevated RNA levels in the HepG2.2.15 cells with the 
enrichment of X peptide through transfection (figure 4.14). Both the HBV pgRNA as well as 
the HBV S transcripts were elevated (figures 4.15). This is consistent with the presumptive 
role of X protein as a transactivator of HBV transcription. The reason why this increase in 
HBV transcript is not reflected in the level of HBV DNA is still entirely clear, but the relative 










Figure 4.16 Detection of HBsAg from supernatants of transfected cells by ELISA 
(Bio-Rad Monolisa HBsAg ultra assay). The reading values of A450 were shown in the 
Y axis. 
 
There was no significant change in the levels of HBsAg detected (Kruskal-Wallis Test, 
p=0.934) in the HepG2.2.15 cell culture medium between the control and the cells enriched 
with the core or the X-peptides (figure 4.16). The reason is not clear but we postulate that as 
the HBsAg is produced at large excess than the virions, a 2-3 fold increase in excreted viral 












4.3  Discussion 
 
We hypothesized that HBV RNA splicing may help to support the viral replication and 
evaluated the effects of adding HBV splice variants and by enriching the viral proteins that 
they are known to produce in two different HBV cell models. In summary, we observed that 
 
1. The co-transfection of HBV spliced genome enhanced the replication of full-length, 
core-associated HBV DNA, and this effect is dose-dependent. 
2. The enrichment of HBV core peptide through the transfection of core-expressing 
plasmid enhanced the production of the intracellular HBV DNA and excreted viral 
DNA (core-associated HBV DNA), but not by increasing the X peptide.  
3. Both the core and the X peptides appear to enhance the HBV pgRNA level, but does 
not lead to an increase in HBsAg secretion by HepG2.2.15 cells. 
 
Part of these findings were independently discovered and published by another group in 2009 
(Ma, Lin et al. 2009). They found that when a hepatocellular carcinoma tissue-derived 
defective spliced genome and its full-length counterpart genome were co-transfected into 
HepG2 cells, the former was shown to enhance the replication of the latter, both by real-time 
PCR and Southern blotting. The enhancing effect was also dose dependent. 
 
However there were several key differences between this publication and our work. Ma et al. 
chosed a rare double-spliced HBV genome to carry out the co-transfection, while we used the 
most common single-spliced variant (type 1), which was report to be the predominant form 
(~80%) in most genotypes (Gunther, Sommer et al. 1997). We believe it would be a more 
representative model to study the pathogenesis mechanism of HBV splice variants. The 
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Chinese group also did not knock out the splice sites of the wild-type genome, which raised 
the concern that a small amount of the spliced RNA may be produced by the control 
experiment and dilute the effects observed. 
 
In the paper, the researchers added a stop codon upstream of the transactivating domains in 
the X gene of the splice variant construct, and the replicative enhancing effect of the double--
spliced variant was abolished (Ma, Lin et al. 2009). The authors thus conclude that the 
replication enhancing competency of the spice variant require an intact HBV X expression 
cassette. Of note the excreted HBeAg titre was also lower with the stop codon at the X gene. 
 
For our project, we too hypothesized that it was the viral proteins coded by the spliced HBV 
RNA that resulted in the replication enhancing property, except that we believe that the core 
was more important than X (for reasons explained below). However we took a different 
approach to evaluate the hypothesis, by independently supplementing the core and X peptides 




4.3.1 The multiple roles of the HBV pregenomic RNA 
 
The HBV pregenomic RNA, besides being the template for reverse transcription by the 
polymerase to synthesis of the genome-length HBV DNA, also served as the messenger RNA 
for the translation of the core peptide, the HBeAg (precore), and the HBV polymerase.  We 
are also aware that a significant fraction of it was spliced to give rise to the HBV spliced 
variants. Although it also has the coding sequences for the surface and X proteins, these are 
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not its natural role as the HBV cccDNA also produces 3 subgenomic mRNAs for the 
translation of the envelope proteins as well as the mRNA for the X protein (Seeger and 
Mason 2000). Thus we do not believe that the X protein translated from the small fraction of 
HBV spliced RNA contribute significantly compared with that produced by dedicated X 
mRNA. 
 
4.3.2  The rate-limiting factor of HBV replication 
 
We hypothesize that the core protein is the rate-limiting factor for HBV replication, and the 
HBV spliced RNA serve as the dedicated core mRNA to achieve a more balanced 
DNA:Polymerase:Core ratio to optimise the viral particles that can be produced. 
 
To produce a single hepatitis B virion, the following components are required (Seeger and 
Mason 2000): 
1. HBV DNA – 1 copy 
2. Polymerase – 1 
3. Core protein – 240 (120 dimer subunits) 
4. Surface proteins – Thousands (produced by dedicated L, M, and S mRNAs) 
5. X protein - Uncertain requirement as a transactivating factor (produced by X mRNA) 
 
Of these, the polymerase and core proteins are translated directly from the HBV pgRNA, and 
their requirements are of the order of 240-folds. Since the polymerase preferentially binds to 
the 5’ end of its own mRNA to initiate reverse transcription and packaging, synthesis of the 
polymerase is apparently sufficient to stop further translation of the pregenome 
(Bartenschlager, Junker-Niepmann et al. 1990, Wang and Seeger 1993). Thus for optimal 
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efficiency, the same pgRNA will have to complete the translation of 240 core proteins before 
synthesizing one polymerase protein, then stop translation completely to become the reverse 
transcription template before being digested by the RNase H activity of the polymerase.  This 
appears to be very improbable even if we accept the assumption that the polymerase open 
reading frame is a less efficient one than the core ORF. Thus numerically, based on our 
current understanding of the viral protein synthesis, core proteins production by the pgRNA 




4.3.3 The localisation and non-structural role of the HBV core protein. 
 
The localisation of the core protein in the cell clearly also affects the availability of core to be 
used for nucleocapsid assembly. It was noticed that HBeAg-positive patients and for anti- 
HBe–positive patients whose disease is in remission (Hsu, Su et al. 1987), staining for 
HBcAg in liver biopsy specimens tends to be nuclear; however, for anti-HBe–positive 
patients with ongoing disease, staining tends to be both nuclear and cytoplasmic (Ballare, 
Lavarini et al. 1989). 
 
The accumulation of core in the nucleus requires active transport and does appear to be 
related to disease and serological status. Jazayeri et al. demonstrated that the pattern of 
HBcAg localization in vitro depends on sequence and the serologic pattern of chronic 
infection, paralleling the situation in vivo (Jazayeri, Dornan et al. 2004). Many separate 
groups of researchers had also observed the association of the core protein with the HBV 
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cccDNA, possibly contributing to the stabilization of the minichromosome (Levrero, 
Pollicino et al. 2009). 
 
Combining the discussion in the last section concerning the supply deficiency of core, and the 
nuclear localisation tendency in many cases, there would be a relative shortage of core 
peptide that can be produced by HBV pgRNA alone, which itself has multiple crucial roles, 
to be available in the cytoplasm for the HBV virion formation.  
 
Thus it makes a compelling argument that by simply making splice donor and acceptor sites 
available, the virus had evolved to hijack the splicing mechanisms of the host cell to convert 
some of its pregenomic RNA to dedicated core mRNA (the splice RNA), by simply removing 
the polymerase coding region. The splice RNA thus can carry out translation of core proteins 
continuously, until a free polymerase protein produced by a wild type pgRNA comes along, 
binds to it and produce the defective viral particles as a byproduct. This model will generate a 
more favourable DNA:Polymerase:Core ratio, and explains the enhanced viral replication 
rate observed with both addition of the splice variant and the core protein. 
 
 
4.3.4 The physiological significance of the enhancement of full-length HBV 
replication  
 
Considering that it only takes one point mutation to remove the splicing capability from the 
wild type HBV genome, the conservation of the splice sites across all the HBV genotypes 
strongly points to a evolutionary selection for its advantage. Our in vitro model of viral 
protein enrichment showed that although both core and X increases the HBV pgRNA levels, 
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only the increased core production resulted in the enhancement of both intracellular and 
excreted encapsidated HBV DNA (the complete virus particles). 
 
Ma et al and our group showed that the HBV replication enhancement effect can be up to 3-5 
folds more than the controls. At the high replication phases of the chronic HBV infection, 
which viral loads can be >108 IU/ml, this enhancement may not appear impressive. However 
at the time of the initial acute HBV infection, when the viral counts were low and immune 
response wwas high, this enhanced viral replication may provide the crucial advantage to 
enable the virus to survive and established itself and progress to chronic infection. It was 
reported that defective particles produced by spliced RNA were detected in a larger amount 
in sera of patients with acute hepatitis that progressed to chronic hepatitis, as compared with 
those who recovered from acute hepatitis (the increase was estimated to be an average of 50-
fold) (Rosmorduc, Petit et al. 1995).  
 
Our group tried to repeat the findings in our patients, but with widespread HBV vaccination 
in our country, acute HBV infection are now rare, and we could not recruit sufficient number 
patients in the study period. 
 
In the next chapter, we attempt to use the small interfering RNA targeting the splice sites to 






Chapter 5: The effects of RNA interference on the HBV splice 
donor and acceptor sites 
 
5.1  Introduction 
 
As the data suggest that HBV spliced RNA enhanced viral replication, we carried out siRNA 




5.1.1  HBV splice sites and PRE as potential therapeutic targets 
 
Small interfering RNA (siRNA) had been widely used to mediate sequence-specific post-
transcriptional silencing of gene expression, by facilitating the degradation of homologous 
mRNA via the formation of the RNA-induced silencing complex (RISC) (Nykanen, Haley et 
al. 2001, Schwarz, Hutvagner et al. 2002).  
 
There had been many publications exploring the use of siRNA targeting various HBV in 
hepatoma cell models (Konishi, Wu et al. 2003, Li, Wasser et al. 2004, Zhang, Xiong et al. 
2004, Chen and Mahato 2008). However here our aim was to examine if siRNA can mediate 
down-regulation of HBV pgRNA splicing, and if this will have additional benefit in 
suppressing the wild-type HBV replication, over the a typical HBV-specific siRNA (S1) that 
was characterised previously (Li, Wasser et al. 2004). We also target the post-transcriptional 
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regulatory element (PRE) to see if this can reduce the unspliced, replication-fit HBV pgRNA 
export to be available for reverse transcription and polymerase translation. 
 
 
5.1.2  Selection of RNAi target sites 
 
We designed three new siRNA duplexes with 2-nt dTdT 3’ overhangs targeting the splice 
donor and splice acceptor sites of the type 1 HBV splice variant, as well as a region at the 
sub-element β1 of the PRE. siRNAs with the most favourable size and thermodynamic 
properties, based on the siRNA design guidelines on the online design tools 1) Invivogen 
siRNA Wizard version 3.1 (http://www.sirnawizard.com/) and siDirect 
(http://sidirect2.rnai.jp/) were identified and ranked to select the most suitable target sites. 
Scrambled siRNA sequence was generated by Invivogen siRNA Wizard for negative control, 
and a published HBV-specified siRNA, S1 (Li, Wasser et al. 2004), was selected to be used 
as positive control. 
 
Scrambled: 5’-GUUUAGCGAUUGGAACAUAdTdT-3’ 
S1 (458-476): 5’-GGUAUGUUGCCCGUUUGUCdTdT-3’  
Splice donor (2442-2460): 5’-GGGAAUCUCAAUGUUAGUAdTdT-3’   
Splice acceptor (488-506): 5’-GGAUCAUCAACAACCAGCAdTdT-3’   
PRE (1374-1392): 5’-ACUCUCCCGCAAGUAUACAdTdT-3’   
 





5.1.3 Optimisation of siRNA transfection efficiency 
 
The scrambled siRNA (negative control) and S1 siRNA (positive control) was used to 
evaluate the transfection protocol. Three different transfection reagents were tested, the 
TransIT TKO transfection reagent (Mirus Bio, Madison, USA), the X-treme GENE HP  and 
the X-treme GENE siRNA transfection reagents (Roche Applied Science, Singapore). 
Varying dose range of S1 siRNA (positive control) and transfection reagent ratio were tested, 
the optimal dose ratio determined by the level of suppression of HBsAg (measure by ELISA), 
and toxicity to the HepG2.2.15 cells at 48 hours after adding the transfection reagent.  
 
The X-treme GENE siRNA transfection reagent  was found to be overall the best transfection 
reagent for the HepG2.2.15 cell line and the dose with greatest HBsAg suppression with least 




5.1.4  Methods 
 
Two cell lines, HepG2.2.15 and Huh7, were used to assess the effectiveness of the splice 
donor/acceptor and PRE siRNAs. As discussed earlier, HepG2.2.15 cells stably produced the 
virus and subviral particles, but does not produce the splice variants, which made it useful to 
evaluate the siRNAs’ general suppressive function on viral gene expression and replication. 
On the other hand, the Huh7 cells, which can be transiently transfected with splice variant 
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producing HBV strains, would permit the study of the specific effect of the newly designed 
siRNAs on the splice variants and wild-type virus production. 
 
2 x 105 HepG2.2.15 or Huh7 cells were seeded into each well of a 24-well plate and allowed 
to recover for 24 h. Before transfection, the appropriate amount of siRNA was diluted in 
Opti-MEM I reduced serum medium to a final concentration of 1 ug siRNA/100 ul. An 
appropriate amount of X-tremeGENE siRNA transfection reagent was added into the medium 
containing the diluted siRNA. After incubation at room temperature for 5 min, these two 
solutions were mixed gently, and incubated for 15 min at room temperature to allow the 
siRNA:X-tremeGENE complexes to form. Cells were then rinsed with Opti-MEM I reduced 
serum medium. Then the siRNA:transfection reagent complex was added to each well and 
mixed gently by rocking the plate back and forth. After introducing the siRNA:transfection 
reagent complexes, the cells were incubated at 37 °C in a CO2 incubator for 48 hours. 
 
Mock transfections were carried out for both cell lines as described above but with the 
omission of the siRNA. reporter plasmid DNA expressing secreted alkaline phosphate 
(SEAP) (Clontech, Mountain View, USA) was used to co-transfect cells as an internal control 
for the normalization of transfection efficiency between plates. At the end of the treatment 
period, the medium was collected for detection of HBsAg, HBeAg (Monolisa, Bio-Rad, 







5.2  Results 
 
5.2.1  Effects of siRNA inhibition of splice donor, splice acceptor, and PRE 
on HBV production in HepG2.2.15 cells 
 
At 48 hours following the treatment of HepG2.2.15 with 0.8 uM and 1.6 uM of each siRNAs 
(see table 5.1 below), there was a significant decrease in intracytoplasmic, core-associated 
HBV DNA in all the wells transfected with S1, Splice donor, Splice acceptor and PRE 



















1&2 Mock transfection - 
3&4 Scrambled 0.8 
5&6 Scrambled 1.6 
7&8 S1 0.8 
9&10 S1 1.6 
11&12 Donor 0.8 
13&14 Donor 1.6 
15&16 Acceptor 0.8 
17&18 Acceptor 1.6 
19&20 PRE 0.8 
21&22 PRE 1.6 
 
Table 5.1 Experiment set up: The type of siRNAs and concentration of the siRNAs 




Figure 5.1 The effects of each siRNA on the levels of the intracytoplasmic, core-
associated HBV DNA in the HepG2.2.15 cells after 48 hours of treatment. 
 
The corresponding culture medium was also test for the level of excreted HBsAg (Figure 
5.2A) and HBeAg (Figure 5.2B). Commercial ELISA kits (Bio-Rad, Singapore) was used to 















Figure 5.2 Detection of HBsAg (A) and HBeAg (B) from supernatants of transfected 
cells by ELISA (Bio-Rad Monolisa HBsAg and HBeAg ultra assay respectively). The 
reading values of A450 were shown in the Y axis. 
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There were modest reduction of the HBsAg levels in the cells transfected with siRNAs S1 
(1.6 uM), Splice donor (1.6 uM), Splice acceptor (0.8 uM and 1.6 uM), and the PRE (0.8 uM 
and 1.6 uM), compared with the mock transfection and scrambled siRNA controls. 
 
For the HBeAg ELISA assay, there were more marked reduction in groups treated with 
siRNA. For reasons not fully understood, the scrambled siRNA appeared to reduce the 
HBeAg levels compared with the mock transfection control. There was likely some 
unintended “off-target” effect on the production or secretion of the viral proteins by the 
scrambled siRNA. However if we compare corresponding groups (i.e. 0.8 uM scrambled 
versus 0.8 uM S1 siRNA, or 1.6 uM scrambled versus 1.6  uM S1), there were significant 
decrease in the HBeAg excreted into the medium with all the targeted siRNAs (S1, splice 
donor, splice acceptor and PRE) compared with the scramble siRNA controls. 
 
In summary, using a stable HBV expressing cell line, HepG2.2.15, that does not produce 
splice variant, we demonstrate that transfection with the siRNAs targeting splice donor, 
acceptor and PRE resulted in reduction in the intracellular HBV DNA, the excreted HBsAg 
and the HBeAg levels. They also performed at least equally well as the published positive 




5.2.2  Effects of siRNA inhibition of splice donor, splice acceptor, and PRE 
on HepG2 cells transfected with HBV genome. 
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Huh7 cells were transiently transfected with splice variant producing HBV strain (233K4, a 
genotype C HBV derived from a liver cancer patient) to study the specific effect of the splice 
donor/acceptor- and PRE-targeting siRNAs on the splice variant and wild-type virus 
production. 
 
5.2.2.1  Transfection of wild-type HBV genome into Huh7 cell line, followed by 
transfection of siRNA. 
 
In brief, 5 x 104 cells Huh7 cells were seeded into each well of a 24-well plate and allowed to 
recover for 24 hours. The wild-type HBV DNA was transfected into the Huh7 cells using 
Effectene transfection reagent (Qiagen, Hilden, Germany). On the day of transfection, 0.2µg 
of 233k4 DNA was diluted in buffer EC to a total volume of 60µl. 1.6µl Enhancer and 5µl 
Effectene transfection reagent was added to the DNA mixture. The samples were incubated 
for 10 minutes at room temperature to allow transfection-complex formation. Fresh growth 
medium (contain FBS and pen-strep) was added to the cells. Finally the transfection 
complexes was added drop-wise on the cells. Incubate the cells with transfection complexes 
for 24 hours.  
 
After transfecting the wild-type HBV DNA for 24 hours, the culture medium was changed 
and proceed immediately with the transfection of siRNA as described in Section 5.1.4. The 
experiment set up (type of siRNA and dose) was identical to that describe in Table 5.1. 
 
Finally the medium containing the XtremeGene transfection reagent was changed after 24 
hours. The cells were harvested 48 hours post-transfection with siRNA, and the DNA and 
RNA extracted using commercial kits as described in Chapter 2. 
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Before all assays, the quantity of HBV DNA was adjusted according to the transfection 
efficacy. For the normalization of transfection efficacy, SEAP expression levels from all 
culture supernatants were measured using the Great EscAPe SEAP Chemiluminescence and 












Figure 5.3 The effects of each siRNA on the levels of the intracytoplasmic, core-
associated HBV DNA in the Huh7 cells after 48 hours of treatment. 
 
In the transient transfected HBV model in the Huh7 cell line, the siRNAs S1, Splice donor, 
Splice acceptor and PRE produced similar decrease in the intracytoplasmic, core-associated 
HBV DNA as they did in the HepG2.2.15 cells (figure 5.3). However the Splice donor 
siRNA required a higher concentration of 1.6 uM to achieve significant reduction, while the 





Figure 5.4 The effects of each siRNA on the levels of the HBV pregenomic RNA in 
the Huh7 cells after 48 hours of treatment. 
 
The HBV pgRNA was performed as described earlier in Section 4.2.2.2. There were 
significant reduction of the HBV pgRNA in those cells treated with S1 (1.6 uM), Splice 




Figure 5.5. Percentage of splice/total HBV DNA after treatment with each siRNAs, 
measured by real-time PCR. 
 
Huh7 cells treated with Splice donor siRNA (0.8 uM and 1.6 uM) and Splice acceptor siRNA  
(1.6 uM) showed significant reduction of the proportion of splice variant DNA (figure 5.5). 
The same proportion was also reduced in the transfected cells treated with S1 0.8 uM for 
unknown reason. As expected, the %SP/Total was higher when the PRE was targeted, which 





Figure 5.6 The relative reduction of intracytoplasmic, core-associated wild-type 
HBV DNA resulting from each siRNA, with respect to the mock transfection control. 
 
To measure the efficacy of each individual siRNA, we compared the percentage reduction of 
the replication fit, genome-length HBV DNA with the mock transfection control. The S1, 
Splice acceptor and PRE siRNAs appear to perform equally well (within margins of error), 









5.3  Discussion 
 
The work in this chapter focused on the effort to target specific HBV splice donor and 
acceptor sites, as well as the related PRE RNA elements responsible for facilitating the 
pregenomic RNA export, using sequence-specific siRNAs to inhibit their functions. 
 
In summary, these siRNAs were as effective as a published siRNA targeting the surface 
mRNA, S1 (positive control), in suppressing viral replication and HBsAg/HBeAg expression. 
Furthermore there were trends towards decreased splice variant production in cells treated 
with Splice donor and acceptor siRNAs, while the PRE siRNA caused the opposite trend  
with more decline in the wild-type viral production.  
 
The RNA interference approach to study the effects of gene silencing is already established 
as one of the basic techniques in molecular biology, mostly because of its specificity and 
consistently robust silencing of gene expression. However, to study the impact of blocking 
the splice donor and acceptor sites, this approach does have its limitation. The siRNA was 
already a very potent agent in silencing the viral gene expression and replication, irregardless 
of which coding region it targets. Thus it may be difficult to show an incremental difference 
in the choice of targeting the RNA splicing or export mechanism. 
 
The other concern was the observation that the transfection of the scrambled siRNA caused a 
decrease in the wild-type HBV DNA (Figure 5.6) and HBeAg (Figure 5.3) production 
compared with the mock transfection control. This could simply be a random effect, but can 
also suggest a direct, unintended effect to the viral or the host gene expression. To solve this, 
there will be a need to repeat the experiments, and consider re-designing new scrambled 
! 164!
siRNA as control. However, from the data, most of our designed siRNAs showed 
significantly greater viral suppression than the scramble siRNA. 
 
In retrospect, we would probably achieve a clearer picture if we had utilised a modified 
antisense oligos, specifically the Morpholino antisense oligos, to specifically inhibit HBV 
splicing. Morpholino oligos are short chains of about 25 Morpholino subunits. Each subunit 
is comprised of a nucleic acid base, a morpholine ring and a non-ionic phosphorodiamidate 
intersubunit linkage. Morpholinos do not degrade their RNA targets, but instead act via an 
RNAse H-independent steric blocking mechanism (see figure 5.7). With their requirement for 
greater complementarity with their target RNAs, Morpholinos are free of the widespread off-
target expression modulation typical of knockdowns which rely on RISC or RNase-H 
activity. They can be designed to modify pre-mRNA splicing in the nucleus by targeting 
splice junctions or splice regulatory sites. Targeting of viral RNA with Morpholinos has been 
reported for hepatitis C, dengue virus, ebola virus, SARS virus, West Nile virus, equine 
arterivirus, mouse hepatitis virus, novirhabdovirus, and vesivirus (Moulton et al. 2008). 
However as our approach was to identify novel therapeutic targets, the intention was to look 
for any additive effect over the typical RNA knockdown through RISC activity, which no 




Figure 5.7   Comparison of RNase H–dependant, RISC-dependant, and steric blocking 
oligos (Moulton et al. 2008). 
 
In the original work published by Li et al. (Li, Wasser et al. 2004) which described the S1 
siRNA (our positive control), the authors noted that although S1 had little effect on the 3.5-kb 
pregenomic RNA (which also contain the HBsAg ORF) but it could still effectively reduce 
the levels of the 2.1-kb/2.4-kb transcripts leading to reduced HBsAg for incorporation into 
the viral envelope. They postulated that there may be secondary structures within the 3.5-kb 
RNA that prevent siRNA-induced cleavage. However our work showed that at higher 
concentration of the S1 siRNA (1.6 uM, rather than the maximum of 0.4 uM in Li et al.) the 
HBV pgRNA was also inhibited (Figure 5.4). Our interpretation was that there was simply 
too many copies of S transcripts that a higher concentration of siRNA was required to clear 
both the S mRNA and the pgRNA. 
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With the proliferation of RNA interference against almost every known gene published in 
literature, the main problem that delays its clinical application is the lack of an efficient and 
safe (non-viral) siRNA delivery system to deliver the siRNA to right target organ. A quick 
literature search revealed no less than 270 publications in the year 2012 alone on this subject 
(Wang and Zhou 2012).  Antisense oligos (ASOs) directed to splice sites or enhancer 
elements will induce exon skipping, whereas ASOs directed to splicing silencer elements will 
enhance exon inclusion. The effectiveness of ASOs has been demonstrated in clinical trials 
for Duchenne muscular dystrophy (DMD), which is caused by partial or complete loss of 
dystrophin function. A large fraction of DMD mutations are genomic deletions such that 
splicing of the remaining exons produce out of frame mRNAs. ASOs are used to induce 
skipping of specific exons to restore the reading frame or remove exons containing mutations 
(Figure 3a) (Hammond et al. 2011). In two independent phase II clinical trials, systemic 
administration of different ASOs targeting exon 51 restored the dystrophin reading frame 
from the mutant gene and increased the number of dystrophin-positive fibers (Goemans et al. 
2011). Our exploratory work here nevertheless adds new potential targets that may be useful 











Chapter 6: Conclusion and Future Work 
 
 
6.1  Summary and Implications 
 
In the earlier chapters, the study focused on how of HBV splice variants can play a role on 
increasing the wild type (WT) viral replication fitness and gain an edge in survival. We made 
a number of interesting findings in the course of this study. 
 
In chapter 3, we demonstrated that the proportions of spliced/WT HBV DNA fluctuates over 
time in the same patient in different phases of HBV infection. Using the real-time PCR assay 
system to quantify the total HBV splice variants, we found that during the immunotolerant 
phase, the splice variant levels were low compare with the wild-type, but this increased 
significantly during immune clearance, peaking just before HBe-seroconversion. We ruled 
out that mutations at the PRE region contributed to this fluctuation, and provided some 
evidence that this phenomenom was due to interferon/other cytokine inhibition of the HBV 
polymerase during immune clearance. 
 
The implications of these findings are that:  
1) Under circumstances such as during the immune clearance phase, or during treatment with 
lamivudine or interferon-alpha, the number of viable, genome-length HBV particles may be 
over-estimated by as much as 4-5 folds, using real-time PCR assays targeting HBV genome 
sequences total (both spliced and unspliced) HBV DNA, resulting in less meaningful false 
positive results;  
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2)  The observation that the proportions of splice variants rise in patients at immune clearance 
phase, peak just before HBeSC, and then fall right after seroconversion may be promising as 
a potential prognotic factor for spontaneous HBe-seroconversion, which may prevent 
unnecessary treatment.  
 
We do stress that due to the small sample size and limited time points, it is still prematured to 
determine the threshold or gradient of rise for making a prediction, and a large, prospective 
cohort of HBV patients in immune clearance phase will be needed to confirm the finding, and 
estimate its positive predictive value. 
 
In chapter 4, we studied the effects of adding HBV splice variants and enriching the viral 
proteins that they are known to produce in HBV cell models, which revealed that: 
 
1. The co-transfection of HBV spliced genome enhanced the replication of full-length, 
core-associated HBV DNA, and this effect is dose-dependent.  
2. The enrichment of HBV core peptide through the transfection of core- expressing 
plasmid enhanced the production of the intracellular HBV DNA and excreted viral 
DNA (core-associated HBV DNA), but not by increasing the X peptide.  
3. Both the core and the X peptides appear to enhance the HBV pgRNA level, but does 
not lead to an increase in HBsAg secretion by HepG2.2.15 cells.  
 
We proposed that by conserving the HBV splice donor and acceptor sites, the virus had 
evolved an ingenious way of  generating a more favourable DNA:Polymerase:Core ratio, and 
thus enhanced viral replication efficiency. It achieved this by converting some of its 
pregenomic RNA to dedicated core mRNA (the splice RNA), by simply removing the 
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polymerase coding region, which can translate into more intracellular core protein production 
(figure 6.1). Our in vitro model of viral protein enrichment showed that although both core 
and X increases the HBV pgRNA levels, only the increased core production resulted in the 
enhancement of both intracellular and excreted encapsidated HBV DNA (the complete 
hepatitis B virion). 
 
Figure 6.1  Proposed model: HBV spliced RNA as subgenomic core mRNA to improve 
the ratio of HBV DNA:Polymerase:Core protein production, contributing to more 
efficient HBV virion production. 
 
In chapter 5, we made an attempt at trying to test the hypothesis that by inhibiting the HBV 
RNA splicing and WT pgRNA export, by targeting the splice donor, acceptor sites and PRE 
region with siRNA, a greater suppression of viral replication may be achieved, than just 
targeting other regions on the HBV pgRNA.  These siRNAs, targeting the splice donor, the 
splice acceptor and PRE sequences, do work to some extent in suppressing viral replication 
and HBsAg/HBeAg expression. Furthermore there were trends towards decreased splice 
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variant production in cells treated with Splice donor and acceptor siRNAs, while the PRE 
siRNA caused the opposite trend (not statistically significant) with more decline in the wild-
type viral production. However we failed to show an incremental difference in the choice of 




6.2    Future work 
 
6.2.1   Background 
 
Hepatitis B splice-generated protein (HBSP) and the host immune system 
 
The HBSP protein is produced from the fusion of a sequence encoding the N-terminal part of 
the polymerase (Pol) and a new ORF created by splicing events. It has been suggested that 
this protein may also play a role in the natural history and pathogenesis of HBV infection 
(Soussan 2003). Antibodies against HBSP have been found in sera from chronic HBV 
carriers, which was significantly associated with severe liver fibrosis and viral replication. 
Various proteins encoded by alternative reading frames (ARF) can activate epitope-specific 
immune responses, which was described in other viral infection (see Section 6.2 below).  
 
Mancini-Bourgine et al. (Mancini-Bourgine, Bayard et al. 2007) used a combination of three 
approaches to identify T-cell epitopes within a recently identified HBV protein encoded by a 
2.2-kb singly spliced HBV RNA. Bioinformatic predictions of peptide-HLA binding and in 
vivo assays with HLA-transgenic mice were used to define HLA-A2- and HLA-B7-restricted 
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epitopes. Overlapping 15-mer peptides spanning the HBSP sequence were used to 
characterize the T-cell responses. HBSP induced potent CD8+ T-cell responses in transgenic 
mice, and recall specific IFN-α-secreting T-cell responses among PBMCs from HBV patients 
in vitro. Using the 15-mer peptide library, CD4+ T-cell responses were activated by HBSP in 
HBV-infected individuals. 
 
A comprehensive analysis of naturally occurring HBV viral sequences in the NCBI database 
(http://www.ncbi.nlm.nih.gov) revealed the existence of several different viral HBSP 
sequences, raising the doubt of its real pathogenetic significance. Despite that, a number of  
regions of the ARF seemed to be immunogenic, as peptide variants derived from other HBV 
strains were still able to reactivate T cells in vitro despite the presence of nonconsensus 
anchor residues (Mancini-Bourgine, Bayard et al. 2007). These T-cell responses activated by 
HBSP may contribute to liver inflammation and damage. 
 
Other viruses with splicing mechanisms – what can we learn? 
 
There was interest in the alternate hypothesis that HBSP may in fact contribute to immue 
tolerance by interfering with the receipt of cytokine signal. 
 
Viruses come equipped with a variety of strategies to alter the interaction of host cytokines 
with their receptors. Perhaps taking an evolutionary cue from soluble cytokine receptors that 
arise from alternative splicing or proteolytic cleavage from the cell surface, there are many 
examples of virus-encoded, secreted cytokine receptors (Spriggs 1996), which are 
particularly prevalent among the large-DNA herpesviruses and poxviruses. It appears that 
many of these homologs of host cytokine receptors serve to compete with cellular receptors 
! 172!
for cytokine binding (McFadden, Lalani et al. 1998). Multiple poxviruses interfere with TNF 
signaling by instructing infected cells to secrete TNFR homologs. These TNFR homologs are 
likely to inhibit the effector functions of TNF, including induction of apoptosis. Cowpox 
virus encodes two such TNFR molecules, CrmB and CrmC, which each bind TNF-α and are 
thought to impede interaction with cellular receptors (Smith, Hu et al. 1996). Myxoma virus 
likewise encodes the TNFR homolog M-T2, which binds TNF-α with similar affinity to that 
of endogenously secreted cytokine receptors. These are just a number of various ways that 
viruses that can interfere with the viral antigen presentation and evade immune detection and 
T-cell activation (Figure 6.1) (Tortorella, Gewurz et al. 2000). 
 
 
Figure 6.2  Viral proteins that interfere with the processing steps of major histocompati- 
bility complex  (MHC) class I antigen presentation (Tortorella, Gewurz et al. 2000). 
EBV, Epstein-Barr virus; ERGIC, ER- Golgi intermediate compartment; HCMV, 
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human cytomegalovirus; HIV, human immunodeficiency virus; HSV, herpes simplex 
virus; MCMV, mouse cytomegalovirus.  
 
 
6.2.2   Does HBSP interfere with HBV antigen presentation and/or T-cell 
activation? 
 
We are planning to work on a model to stably expressed the HBSP (derived from our clinic 
sample) in the HepG2.2.15 cell line, which can co-express the wild-type HBV and HBSP. 
This will be carried out in collaboration with the Hepatitis B Infection and Immunity 
Programme of the Singapore Institute for Clinical Sciences, to apply the cell model to 
evaluate the effects of regulated expression of HBSP on the viral antigen presentation and T-
cell activation. 
 
Our approach is to introduce the HBSP-expressing cassette into HepG2.2.15 cells (which was 
already integrated with HBV genome and expressed no splice products) with the Tet-on 
Advance Inducible Gene Expression by Clontech Laboratories (Mountain View, USA). This 
system requires double-stable transfection of a regulatory plasmid and a response plasmid 
containing the gene-of-interest. The expression of the gene-of-interest can then be regulated 
by the concentration of Doxycycline of the cell culture medium. A series of controlled HBSP 
levels will be tested against validated HBV-specific T cells, to determine if the HBV antigen 





6.2.3   HBV splice variant as  new marker for predicting  HBe-
seroconversion 
 
As discussed earlier in Section 3.3.2, our work suggest that a rise in the HBV splice variant 
may predict the occurrence of HBe-seroconversion, with is a clinical signpost for a transition 
into the inactive phase. The exact cut-off and the predictive value is not known. Whether it 
can be used as a independent predictor, or combine with another marker, eg. the quantitative 
HBsAg assay, remained unclear until a large prospective cohort can be carried out. 
 
A new “National University Hospital Chronic Hepatitis B Cohort” study will prospectively 
monitor a large group of clinic patients with standardised medical record and collection of 
their serum samples at each of the patients’ clinic visits.  The aim is to recruit 100 patients in 
the immune clearance phase to validate the results. 
 
 
6.2.4  HBV splice variant and HBeAg negative reactivation 
 
With the increasing age of the average chronic HBV patients in Singapore, more  patients are 
now in the HBeAg negative phase. Amongst this group, many will reactivate at some point in 
their natural history. 
 
Based on the preliminary data in Section 3.2.4, there appear to be a rising trend of the 
proportion of the HBV splice variants towards a peak and then fall around the time of a flare 
due to HBV reactivation. It can certainly be the effect of cytokines relating to the viral 
! 175!
reactivation, except that instead of a falling HBV DNA during the immune clearance phase, 
the viral load was actually sharply increased during the reactivation. 
 
Twenty patients with appropriate samples will be collected before, during and after the HBe-
negative reactivation. The HBV DNA will be extracted and tested using the splice variant 
qPCR assay as described earlier. If the relationship is confirmed, we would examine the time 
points prior to the reactivation event to see if these can be predicted based on the changes in 
the splice variant levels. 
 
 
6.2.5  HBV RNA splicing as a potential therapeutic target 
 
A very brief explanation about the eukaryotic RNA splicing machinery in Section 1.3.2, 
which is in a fact a highly complex and regulated process. The principle mechanism is 
catalyzed by a large ribonucleoprotein (RNP) complex termed the spliceosome, composed of 
the five snRNPs U1, U2, U4, U5, and U6 and a large number of non-snRNP proteins. 
Spliceosomes assemble in a stepwise manner and thus pass through a series of distinct 
complexes. Initially, the U1 and U2 snRNPs bind the pre-mRNA, forming the A complex. 
Subsequently, the U4/U6.U5 tri-snRNP associates, and the precatalytic B complex is 
generated. After major rearrangements resulting in the displacement of U1 and U4, the 
activated spliceosome is formed, followed by additional restructuring and catalysis of step 1 
of splicing. This involves cleavage at the 5’ splice site of the pre-mRNA and the ligation of 
the 5’ end of the intron to the branch site to form a lariat-like structure. This leads to 
formation of the spliceosomal C complex, which catalyzes step 2 of splicing, during which 
the intron is excised and the exons are ligated together to form mRNA. Subsequently, the 
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spliceosome dissociates, and the snRNPs are recycled for additional rounds of splicing 
(Wahl, Will et al. 2009). 
 
The work on the RNA interference to inhibit the splice donor and acceptor site represents one 
approach to target HBV splicing as a therapeutic target. Aberrant pre-mRNA splicing is 
associated with many human diseases, including cancer, and neurodegenerative and 
autoimmune diseases, making the spliceosome a highly attractive drug target (Tazi, Durand et 
al. 2005). To date, only a limited number of small-molecule inhibitors of pre-mRNA splicing 
have been identified. These include antibiotics (erythromycin, chlortetracycline, and 
streptomycin) (Hertweck, Hiller et al. 2002), a biflavanoid (isoginkgetin) (O’Brien et al. 
2008), inhibitors of the kinase activity of topoisomerase I (Pilch et al. 2001; Tazi et al. 
2005a), antitumor drugs targeting the U2 snRNP—i.e., spliceostatin A (Kaida et al. 2007) and 
pladienolide (Kotake et al. 2007)—selected inhibitors of histone deacetylases and histone 
acetyltransferases (Kuhn et al. 2009), lichen secondary metabolites (Samatov et al. 2012), and 
1,4-naphthoquinones and 1,4-heterocyclic quinones with known anticancer activity (Berg et 
al. 2012). The specific spliceosome targets of these compounds have been identified in only a 
few cases. They were also never evaluated from the angle of inhibiting HBV RNA splicing, 
and could offer potential benefit with manageable side effects (some of the antibiotics were 
already in widespread clinical use for decades). 
 
There are certainly valid concerns relating to targeting spliceosome as an approach to 
antiviral therapy. Alternate splicing of genes is essential for regulating gene expression 
contributing to functional complexity. It is known that in humans, mutations in the cis-
elements cause mis-splicing of genes that alter gene function and contribute to disease 
pathology. Mutations of core spliceosomal factors are associated with hematolymphoid 
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neoplasias, retinitis pigmentosa, and microcephalic osteodysplastic primordial dwarfism type 
1 (MOPD1). Mutations in the trans-regulatory factors that control alternative splicing are 
associated with autism spectrum disorder, amyotrophic lateral sclerosis (ALS), and various 
cancers. However robust approaches are developed using modified antisense oligos (ASOs) 
targeted to specific RNA sequences to specifically redirect splicing. ASOs directed to splice 
sites or enhancer elements will induce exon skipping, whereas ASOs directed to splicing 
silencer elements will enhance exon inclusion. The effectiveness of ASOs has been 
demonstrated in clinical trials for Duchenne muscular dystrophy (DMD), which is caused by 
partial or complete loss of dystrophin function (Singh et al. 2012).   
 
A number of small molecules targeting aberrant splicing had been identified by large-scale 
screens or strategic chemical design and are finding their way into antitumour therapy. For 
example spliceostatin A (SSA) target protein is also a component of the SF3b complex, 
however, instead of general splicing inhibition, SSA produced alternative splicing changes in 
cell cycle genes (Corrionero et al. 2011). Pladienolide B and SSA inhibit formation of 
complex A, and early steps of spliceosome assembly (Figure 1), whereas isoginkgetin inhibits 
progression of complex A to complex B (O’Brien et al. 2008). It may be possible to identify 
small compounds that affect the activities of specific splicing factors that disrupt HBV-
associated splicing pathways to minimise potential side effects. 
 
Our future work will include testing some of these compounds in HBV-producing cell lines 
to see if their anti-spliceosome effects can be extended to the inhibition of HBV splicing and 
replication. If so, some of these drug may be considered for clinical trials in combination with 
current antivirals for complementary effect against the chronic HBV infection. 
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6.3  Conclusion 
 
The work presented in this thesis demonstrates that the HBV splice variants fluctuates over 
time in the same patient in different phases of the natural history of HBV infection. During 
the immunotolerant phase, the splice variant levels were low compare with the wild-type, but 
this increased significantly during immune clearance, peaking just before spontaneous HBe-
seroconversion. The same pattern was demonstrated in lamivudine and interferon-α-treated 
patients, supporting the hypothesis that the mechanism for the relative increase in the splice 
variant DNA is through the inhibition of the HBV polymerase. In immune clearance phase, 
the antiviral effect of interferon  is probably responsible for direct or indirect inhibition of the 
polymerase function. We ruled out the alternative hypothesis that mutations at the PRE 
region contributed to this fluctuation. 
 
The other major finding was that the most common single-spliced defective HBV genome 
(SP1) enhanced replication of full-length, core-associated HBV DNA. We postulate that the 
spliced RNA served as dedicated core mRNA, increase the amount of core available in the 
cytoplasm to form the viral nucleocapsid. First of all, it takes 240 times more of core protein 
than the HBV DNA or the polymerse to form a single hepatitis B virion. Furthermore core 
protein is actively transported into the nuclus, resulting in greater deficiency in the 
cytoplasm. An earlier study had proved convincingly that transfected splice variant DNA 
produced 20-fold more core protein than transfected HBV DNA (Rosmorduc, Petit et al. 
1995). In our own experiment, core enrichment through transfected core-expression plasmid, 
just like the splice variant DNA, increased the HBV DNA and pregenomic RNA production, 
indicating that core is the rate-limiting factor of viral replication. Finally siRNA blocking the 
splice donor and acceptor sites caused a reduction in HBV DNA and pgRNA, although it is 
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more difficult to ascertain that this is a general RNAi effect or specifically due to splice 
inhibition. 
 
Overall this work improved our understanding of the importance of HBV RNA splicing in the 
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A.   Reagents and Equipment  
 
1. Source of chemicals and reagents  
BDH LABORATORY SUPPLIES, Poole, Dorset, England: Glycerol, paraformaldehyde (PFA), Tris-
HCl, Tris-base (Trizma). 
BECTON DICKINSON, Franklin Lakes, USA: BactoTM Agar. 
BIO-RAD LABORATORIES, Hercules, USA: Acrylamide/bisacrylamide, agarose, ammonium 
peroxide sulphate, mixed bed resin, N,N,N,N-tetramethyl-ethylenediamine (TEMED) and urea. 
BMA, ROCKLAND, USA: Gelstar nucleic acid gel stain. 
CALBIOCHEM, Darmstadt, Germany: Mounting media. 
DECKGLASER, Germany: Slides and coverslips. 
E MERK, Germany: Absolute alcohol, hydrochloric acid, methanol. 
FINNZYMES OY, Espoo, Finland: DYNAzyme EXTTM Taq DNA polymerase . 
FMC BIOPRODUCTS, Rockland, USA: NuSieve agarose. 
GENSET Singapore Biotech. Pet ltd, Singapore: All primers 
GIBCOBRL Life Technologies, Carlsbad, USA: 1 kb plus DNA ladder, L-glutamine, MEM-non-
essential amino acid, MEM-sodium pyruvate trypsin-EDTA. 
NATIONAL UNIVERSITY MEDICAL INSTITUTES (NUMI), laboratory supply: autoclaved 
Dulbecco’s Modified Eagle’s Media (DMEM), 10 × TAE buffer (pH 8), 5 × TBE buffer (pH 8.3), 1M 
Tris (pH 7.4), 1 × PBS buffer (pH 7.5), 10 × PBS buffer (pH 7.5) and LB broth. 
NEW ENGLAND BIOLABS, USA: 100 bp DNA ladder, 1kb DNA ladder, restriction enzymes with 
buffers and T4 DNA ligase with buffer. 
PE BIOSYSTEMS, USA: Blue Dextran/EDTA (sequencing loading dye). 
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PROMEGA, Madison, USA: dATP, dCTP, dGTP, dTTP. 
SIGMA CHEMICAL COMPANY, USA: ampicillin, β-mercaptoethanol, bovine serum albumin, 
bromophenol blue, calcium chloride, Diethyl Pyrocarbonate (DEPC), ethidiumbromide, formamide, 
isopropylthio-β-D-galactoside (IPTG), isopropanol, sodium acetate, sodium chloride, sodium 
deodecyl sulphate (SDS), ethylene diamine tetra-acetic acid (EDTA), 5-bromo-4-chloro-3-indolyl- β-
D-galactoside (X-gal), saponin, and xylene cyanol; Tritc conjugated rabbit anti-mouse Ig-G antibody. 
US BIOLOGICAL, USA: Mouse anti-hepatitis B e antigen. 
 
2. Source of kits and systems 
ABBOTT LABORATORIES, USA: Anti-delta EIA diagnostic kit, anti-HBe EIA diagnostic kit, HBe 
2.0 IMX diagnostic kit and HIV-EIA diagnostic kit. 
BIO 101, USA: Geneclean II kit. 
MILLIPORE, USA: Syringe filter (0.22 µm). 
INVITROGEN, USA: Superscript RT-PCR kit, pcDNA6/V5-His vector. 
PE BIOSYSTEMS, USA: ABI Prism BigDye terminator cycle sequencing ready reaction kit. 
PROMEGA, Madison, USA: Wizard Miniprep kit, pGEM-T and pGEM-T easy vector systems, β-
galactosidase enzyme assay system with reporter lysis buffer. 
ROCHE, Germany: Amplicor HBV monitorTM test kit. 
QIAGEN, Germany: DNA Blood Mini kit, Effectene transfection kit, Hot star Taq PCR kit and 
RNeasy mini kit 
 
3. Source of equipment 
ABBOTT LABORATORIES (USA): IMXSYSTEM. 
B. BRANUN BIOTECH INTERNATIONAL: Shaker incubator (CERTOMAT BS-1) 
BECTON DICKINSON, USA: Petri dish, cell culture plates and flasks, 15ml and 50 ml Falcon tubes, 
5 ml, 10ml and 25ml of pipettes, and pipet-aid with T.C. filter. Beckman, USA: AllegraTM 64 R 
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Centrifuge. 
BIO-RAD, USA: Power/PAC 200; Horizontal wide mini-sub cell GT, mini-sub cell GT, and the 
DcodeTM universal mutation detection system. 
EPPENDORF, Hamburg, Germany: Centrifuge 5415C, centrifuge 5415D, Concentrator 5301, 1.5 ml 
microcentrifuge tubes and 0.2ml of PCR tubes. 
GIBCO BRL, Carlsbad, USA: Electrophoresis power supply 250EX. 
HOEFER PHARMACIA BIOTECH INC, USA: Hoefer SG100 Gradient maker. 
HAMLTON, USA: Multiple channel syringes. 
HIRAYAMA, Japan: Autoclave (HVE-50). 
IMPROVED NEUBAUR, USA: Hausser Scientific hemocytometer. 
KODAK, USA: Polarid camera; Polaroid T 667 film, film developer and x-ray film cassette. 
NALGE COMPANY, USA: Bottle filter (0.22 µm). 
NESLAB endocal, USA: Water bath. NUAIRTM , USA: Biological safety cabinet Class II (NU-440-
400E). 
OLYMPUS, Japan: Olympus IX 70 inverted microscope and SLUOVIEW 300 confocal microscope. 
PERKIN ELMER (USA): ABI PRISM 377 sequencer and ABI PRISM 377 XL collector sequencing 
analysis software version 3.41. 
PHARMACIA BIOTECH, England: Ultro spec 2000 spectrophotometer. 
SANYO electric Co. Ltd.: CO2 Incubator. 
TECAN Group Ltd., Maennedorf, Switzerland: Sunrise - absorbance reader. 
THERMOLYNE, USA: Vortex (Maxi MixII 37600 Mixer). 
VIBER LOUR MAT, France: UV transilluminator. 
WHATMAN BIOMETRA, Maidstone, UK: T3 Thermocycler (DNA cycler). 
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B. Buffers and solutions  
 
10% (w/v) Ammonium peroxide sulphate (APS) 1 g of ammonium peroxide dissolved in 10 ml of 
distilled water and stored in the dark at – 20oC until use. 
Ampicillin stock solution 
Ampicillin was dissolved in distilled water to give a final concentration of 100 mg/ml. The solution 
was then filtered with a 0.22 mm syringe filter and stored at – 20oC. 
Complete Dulbecco’s Modified Eagle’s Media (DMEM) 
10 ml of L-glutamine (100×), MEM-non-essential amino acid (100 ×), Penicillin- Streptomycin 
(100×), MEM- sodium pyruvate solution (100 ×) and 100 ml of fetal bovine serum were added in the 
860 ml DMEM supplied by NUMI and mixed well before use. 
10 x DNA Loading Buffer 10ml 
5 ml Glycerol, 5 mg of bromophenol blue, 400 µL of 0.5 M EDTA were mixed with distilled water to 
a final volume of 10 ml and stored at room temperature. 
Ethidium bromide stock solution (1%) 
0.1 g Ethidium bromide was dissolved in 100 ml of distilled water and stored at 4oC in the dark. 
Gelstar stain solution for DGGE gel 
5 ml of Gel star was mixed well with 50 ml of 1 × TAE buffer, pH 8 before use. 
IPTG stock solution (0.2M) 
1.2 g IPTG dissolved in 25 ml of distilled water was filtered and stored at 4 oC. 
LB Agar 
7.5 g of agar were dissolved in 500 ml of LB broth and autoclaved. 
LB broth with ampicillin 
500 ml of 100 mg/ml ampicillin solution were added into 500 ml of LB broth to give a concentration 
! 196!
of 0.1 mg/ml. It was prepared when required. 
LB agar with ampicillin 
500 ml of 100 mg/ml stock ampicillin solution were added to 500 ml of autoclaved LB agar liquid 
(around 50 oC) and mixed well before pouring the plates. 
LB agar with ampicillin, X-gal and IPTG 
1.25 ml of IPTG stock solution and 0.8 ml of X-Gal stock solution were added into the LB agar with 
ampicillin liquid and mixed well to pour the plates. 
0.1 M CaCl2 
3.675g of CaCl2 dissolved in distilled water to a final volume of 1 L was autoclaved and stored at 4 
oC until required. 
0.2 M EDTA, pH 8.0, 2 ml 
1 ml of 0.2 M EDTA pH 8.0 and 400 ml of 0.5 M EDTA were mixed with 600 ml of double distilled 
water. 
3.7% PFA 10 ml 
3.7gofPFAwasdissolvedwith 10mlof1×PBSpH7.4 
0.1% Saponin 
0.1 g of saponin was dissolved in 1 × PBS. 
TE (Tris/EDTA) Buffer pH 7.4, 100 ml 
1 ml of 1 M Tris, pH 7.4, (10mM) and 0.2 ml of 0.5M EDTA (pH 8.0) (1mM) were mixed and topped 
up to 100 ml with double distilled water. 
X-Gal stock 
100 mg of 5-bromo-4-chloro-3-indolyl-b-D-galactoside (x-gal) were dissolved in 2 ml of N,N’- 
dimethylformamide and stored at -20oC in the dark. 
 
